Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use

ABSTRACT

This invention provides novel peptides that function in vivo to stimulate insulin release from pancreatic beta cells in a glucose-dependent fashion. These insulin secretagogue peptides are shown to stimulate insulin release in rat islet cells in vitro, and in vivo. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, in particular type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VIP/PACAP-related polypeptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptides to said mammal. Also disclosed are methods of making the peptides, both recombinant and synthetic.

FIELD OF THE INVENTION

This invention relates to newly identified polypeptides and the use ofsuch polypeptides for therapeutic purposes. More particularly, thepolypeptides of the present invention are useful in stimulating therelease of insulin from pancreatic beta cells in a glucose-dependentmanner, thereby providing a treatment option for those individualsafflicted with a metabolic disorder such as diabetes or impaired glucosetolerance, a prediabetic state.

BACKGROUND OF THE RELATED ART

Diabetes is characterized by impaired glucose metabolism manifestingitself among other things by an elevated blood glucose level in thediabetic patient. Underlying defects lead to a classification ofdiabetes into two major groups: type I diabetes, or insulin dependentdiabetes mellitus (IDDM), which arises when patients lack beta-cellsproducing insulin in their pancreatic glands, and type 2 diabetes, ornon-insulin dependent diabetes mellitus (NIDDM), which occurs inpatients with an impaired beta-cell function and alterations in insulinaction.

Type I diabetic patients are currently treated with insulin, while themajority of type 2 diabetic patients are treated with agents thatstimulate beta-cell function or with agents that enhance the tissuesensitivity of the patients towards insulin. Over time almost one-halfof type 2 diabetic subjects lose their response to these agents and thenmust be placed on insulin therapy. The drugs presently used to treattype 2 Diabetes include:

Alpha-glucosidase inhibitors (PRECOSE®, VOGLIBOSE™, and MIGLITOL®).Alpha-glucosidase inhibitors reduce the excursion of postprandialglucose by delaying the absorption of glucose from the gut. These drugsare safe and provide treatment for mild to moderately affected diabeticsubjects. However, gastrointestinal side effects have been reported inthe literature.

Insulin sensitizers. Insulin sensitizers are drugs that enhance thebody's response to insulin. Thiozolidinediones such as REZULIN™(troglitazone) activate the PPAR gamma receptor and modulate theactivity of a set of genes that have not been well described. Althougheffective, these drugs have been associated with liver toxicity. Becauseof hepatotoxicity, REZULIN has been withdrawn from the market.

Insulin secretagogues (sulfonylureas and other agents that act by theATP-dependent K+ channel). SFUs are standard therapy for type 2diabetics that have mild to moderate fasting glycemia. The SFUs havelimitations that include a potential for inducing hypoglycemia, weightgain, and high primary and secondary failure rates. 10 to 20% ofinitially treated patients fail to show a significant treatment effect(primary failure). Secondary failure is demonstrated by an additional20-30% loss of treatment effect after six months on an SFU. Insulintreatment is required in 50% of the SFU responders after 5-7 years oftherapy (Scheen, A. J., et al., Diabetes Res. Clin. Pract. 6:533-543(1989)).

GLUCOPHAGE™ (mefformin HCl) is a biguanide that lowers blood glucose bydecreasing hepatic glucose output and increasing peripheral glucoseuptake and utilization. The drug is effective at lowering blood glucosein mildly and moderately affected subjects and does not have the sideeffects of weight gain or the potential to induce hypoglycemia. However,GLUCOPHAGE has a number of side effects including gastrointestinaldisturbances and lactic acidosis. GLUCOPHAGE is contraindicated indiabetics over the age of 70 and in subjects with impairment in renal orliver function. Finally, GLUCOPHAGE has the same primary and secondaryfailure rates as the SFUs.

Insulin treatment is instituted after diet, exercise, and oralmedications have failed to adequately control blood glucose. Thistreatment has the drawbacks that it is an injectable, that it canproduce hypoglycemia, and that it causes weight gain.

Because of the problems with current treatments, new therapies to treattype 2 diabetes are needed. In particular, new treatments to retainnormal (glucose-dependent) insulin secretion are needed. Such new drugsshould have the following characteristics: dependent on glucose forpromoting insulin secretion, i.e. produce insulin secretion only in thepresence of elevated blood glucose; low primary and secondary failurerates; and preserve islet cell function. The strategy to develop the newtherapy disclosed herein is based on the cyclic adenosine monophosphate(cAMP) signaling mechanism and its effects on insulin secretion.

Cyclic AMP is a major regulator of the insulin secretion process.Elevation of this signaling molecule promotes the closure of the K+channels following the activation of protein kinase A pathway. Closureof the K+ channels causes cell depolarization and subsequent opening ofCa++ channels, which in turn leads to exocytosis of insulin granules.Little if any effects on insulin secretion occurs in the absence of lowglucose concentrations (Weinhaus, A., et al., Diabetes 47: 1426-1435(1998)). Secretagogues like pituitary adenylate cyclase activatingpeptide (“PACAP”) and GLP-1 use the cAMP system to regulate insulinsecretion in a glucose-dependent fashion (Komatsu, M., et al., Diabetes46: 1928-1938, (1997)). Insulin secretagogues working through theelevation of cAMP such as GLP-1 and PACAP is also able to enhanceinsulin synthesis in addition to insulin release (Skoglund, G. et al.,Diabetes 49: 1156-1164, (2000). Borboni, P. et al., Endocrinology 140:5530-5537, (1999)).

PACAP is a potent stimulator of glucose-dependent insulin secretion frompancreatic beta-cells. Three different PACAP receptor types (R1, R2, andR3) have been described (Harmar, A. et al., Pharmacol. Reviews 50:265-270 (1998)). PACAP displays no receptor selectivities, havingcomparable activities and potencies at all three receptors. R1 islocated predominately in the CNS, whereas R2 and R3 are more widelydistributed. R2 is located in the CNS as well as in liver, lungs andintestine. R3 is located in the CNS, pancreas, skeletal muscle, heart,kidney, adipose tissue, testis and stomach. Recent work argues that R3is responsible for the insulin secretion from beta cells (Inagaki, N. etal., PNAS 91: 2679-2683, (1994)). This insulinotropic action of PACAP ismediated by the GTP binding protein Gs. Accumulation of intracellularcAMP in turn activates the nonselective cation channels in beta cellsincreasing [Ca++], and promotes exocytosis of insulin-containingsecretory granules.

PACAP is the newest member of the superfamily of metabolic,neuroendocrine and neurotransmitter peptide hormones that exert theiraction through the cAMP-mediated signal transduction pathway (Arimura,Regul. Peptides 37:287-303 (1992)). The biologically active peptides arereleased from the biosynthetic precursor in two molecular forms, eitheras a 38-amino acid peptide (PACAP-38) and/or as a 27-amino acid peptide(PACAP-27) with an amidated carboxyl termini (Arimura, supra).

The highest concentrations of the two forms of the peptide are found inthe brain and testis (reviewed in Arimura, supra). The shorter form ofthe peptide, PACAP-27, shows 68% structural homology to vasoactiveintestinal polypeptide (VIP). However, the distribution of PACAP and VIPin the central nervous system suggests that these structurally relatedpeptides have distinct neurotransmitter functions (Koves et al.,Neuroendocrinology 54:159-169, (1991)).

Recent studies have demonstrated diverse biological effects of PACAP-38,from a role in reproduction (McArdle, Endocrinology 135:815-817 (1994))to ability to stimulate insulin secretion (Yada et al., J. Biol. Chem.269:1290-1293 (1994)).

Vasoactive intestinal peptide (VIP) is a 28 amino acid peptide that wasfirst isolated from hog upper small intestine (Said and Mutt, Science169: 1217-1218, 1970; U.S. Pat. No. 3,879,371). This peptide belongs toa family of structurally-related, small polypeptides that includeshelodermin, secretin, the somatostatins, and glucagon. The biologicaleffects of VIP are mediated by the activation of membrane-bound receptorproteins that are coupled to the intracellular cAMP signaling system.These receptors were originally known as VIP-R1 and VIP-R2, however,they were later found to be the same receptors as PACAP-R2 and PACAP-R3.VIP displays comparable activities and potencies at PACAP-R2 andPACAP-R3.

To improve the stability of VIP in human lung fluid, Bolin et al(Biopolymers 37: 57-66, (1995)) made a series of VIP variants designedto enhance the helical propensity of this peptide and reduce proteolyticdegradation. Substitutions were focused on positions 8, 12, 17, and25-28, which were implicated to be unimportant for receptor binding.Moreover, the “GGT” sequence was tagged onto the C-terminus of VIPmuteins with the hope of more effectively capping the helix. Finally, tofurther stabilize the helix, several cyclic variants were synthesized(U.S. Pat. No. 5,677,419). Although these efforts were not directedtoward receptor selectivity, they yielded two analogs (designated hereinas R3P0 and R3P4) that have greater than 100-fold PACAP-R3 selectivity(Gourlet et al., Peptides 18: 403-408, (1997); Xia et al., J. Pharmacol.Exp. Ther., 281: 629-633, (1997)).

GLP-1 is released from the intestinal L-cell after a meal and functionsas an incretin hormone (i.e. it potentiates glucose-induced insulinrelease from the pancreatic beta-cell). It is a 37-amino acid peptidethat is differentially expressed by the Glucagon gene, depending upontissue type. The clinical data that support the beneficial effect ofraising cAMP levels in β-cells have been collected with GLP-1. Infusionsof GLP-1 in poorly controlled type 2 diabetics normalized their fastingblood glucose levels (Gutniak, M., et al., New Eng. J. Med.326:1316-1322, (1992)) and with longer infusions improved the beta cellfunction to those of normal subjects (Rachman, J. et al., Diabetes 45:1524-1530, (1996)). A recent report has shown that GLP-1 improves theβ-cells' ability to respond to glucose in subjects with impaired glucosetolerance (Byrne M., et al., Diabetes 47: 1259-1265 (1998)). All ofthese effects, however, are short-lived because of the short half-lifeof the peptide. Recently Novo Nordisk has discontinued clinical trialswith GLP-1. This failure reportedly was due to a very short plasmahalf-life of the peptide of a few minutes.

EXENDIN 4™. Amylin Pharmaceuticals is conducting Phase I trials withEXENDIN 4 (AC2993), a 39 amino acid peptide originally identified inGila Monster. Phase II trials have recently begun. Amylin claimspreclinical results showing a 4 hour duration of efficacy and efficacyin animal models when AC2993 is administered subcutaneously, orally, andnasally. However, at doses of 0.2 and 0.3 ug/kg, the incidence ofheadaches, postural hypotension, nausea and vomiting was significant.

There exists a need for an improved peptide that has theglucose-dependent insulin secretagogue activity of PACAP, GLP-1, orEXENDIN 4, and yet has fewer side-effects.

SUMMARY OF THE INVENTION

This invention provides novel polypeptides that function in vivo asagonists of the PACAP R3 receptor (hereafter, R3) and are effective inthe treatment of diseases and conditions that can be ameliorated byagents having R3 agonist activity. Preferably, the polypeptides of thisinvention are selective R3 agonists, having greater potency at R3 thanat R2 and R1. For example, but not by way of limitation, thesepolypeptides stimulate insulin synthesis and release from pancreaticbeta cells in a glucose-dependent fashion and subsequent plasma glucosereduction. These insulin secretagogue polypeptides are shown tostimulate insulin release in rat and human islet cells in vitro and invivo. Unlike PACAP-27, these secretagogue polypeptides also lower bloodglucose in vivo more than vehicle control upon glucose challenge.

The polypeptides of the present invention provide a new therapy forpatients with, for example, metabolic disorders such as those resultingfrom decreased endogenous insulin secretion, in particular type 2diabetics, or for patients with impaired glucose tolerance, aprediabetic state that has a mild alteration in insulin secretion.

In particular, one aspect of the invention is a polypeptide selectedfrom the group consisting of SEQ ID NOs: 11 through 14, SEQ ID NO: 18,SEQ ID NOs: 21 through 26, SEQ ID NOs: 32 through 36, SEQ ID NOs: 40through 53, SEQ ID NOs: 57 through 61, SEQ ID NOs: 63 through 99, SEQ IDNOs: 102 through 119, SEQ ID NOs: 121 through 137, SEQ ID NOs: 139through 177, SEQ ID NOs: 179, 180, SEQ ID NOs: 183 through 202, 322through 341, and fragments, derivatives and variants thereof thatdemonstrate at least one biological function that is substantially thesame as the polypeptides of the listed SEQ ID NOs. (collectively,“polypeptides of this invention”), including functional equivalentsthereof. A preferred embodiment of this invention is a polypeptideselected from the group consisting of SEQ ID NOs. 12, 18, 21-26, 32-35,41, 43-53, 63, 66, 70-92, 94-99, 102-104, 107, 109, 112-119, 121-137,139, 140, 142-153, 156-174, 187, 322 through 341, and fragments,derivatives, and variants thereof that demonstrate at least onebiological function that is substantially the same as the polypeptidesof the listed SEQ ID NOs. A more preferred embodiment of this inventionis a polypeptide selected from the group consisting of SEQ ID NOs 18,24, 25, 32, 33, 43-50, 52, 53, 70-87, 92, 98, 99, 104, 107, 112-114,129-131, 137, 140, 144, 147-151, 156-159, and 161-173, 323, 324, 326,327, 335, 338, 341, and fragments, derivatives and variants thereof thatdemonstrate at least one biological function that is substantially thesame as the polypeptides of the listed SEQ ID NOs. A most preferredembodiment of this invention is a polypeptide selected from the groupconsisting of SEQ ID NOs 18, 32, 43, 45, 47, 50, 52, 71, 72, 83, 86, and87, and fragments, derivatives and variants thereof that demonstrate atleast one biological function that is substantially the same as thepolypeptides of the listed SEQ ID NOs.

Another embodiment of the invention is a polynucleotide that encodes forthe polypeptides of this invention, and the attendant vectors and hostcells necessary to recombinantly express the polypeptides of thisinvention. These polynucleotide sequences include those identified asSEQ ID NOs: 204, 207-211, 214-230, and 232-321. Preferredpolynucleotides include those identified as SEQ. ID. NOs 204, 207-209,215, 217-230, 232-234, 237, 239, 242-268, 270-281, and 284-321. Morepreferred polynucleotides include those identified as SEQ ID NOs 207,218-224, 226-230, 234, 237, 242-244, 258-260, 266, 268, 272, 275-279,284-287, 289-301, and 303, 304, 306, 307, 318, and 321. Most preferredpolynucleotides include those identified as SEQ ID NO 217, 221, and 226.

Antibodies and antibody fragments that selectively bind the polypeptidesof this invention are also provided. Such antibodies are useful indetecting the polypeptides of this invention, and can be identified andmade by procedures well known in the art, including those analogous tothat described in Example 17 below.

The invention is also directed to a method of treating diabetes and/orother diseases or conditions affected by the polypeptides of thisinvention, preferably effected by the R3 agonist function of thepolypeptides of this invention, in a mammal, comprising administering atherapeutically effective amount of any of the polypeptides of thepresent invention or any polypeptide active at R3 such as SEQ ID NO 5and 9 to said mammal.

Also disclosed are methods of making the polypeptides of this invention,both recombinant and synthetic.

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1 depicts amino acid sequences of polypeptides of SEQ ID NO: 11through 14, SEQ ID NO: 18, SEQ ID NOs: 21 through 26, SEQ ID NOs: 32through 36, SEQ ID NOs: 40 through 53, SEQ ID NOs: 57 through 61, SEQ IDNOs: 63 through 99, SEQ ID NOs: 102 through 119, SEQ ID NOs: 121 through137, SEQ ID NOs: 139 through 177, SEQ ID NOs: 179, 180, SEQ ID NOs: 183through 202, and SEQ ID NOs: 322 through 341 which are claimedpolypeptides.

FIG. 2 is a sequence alignment of VIP mutants and native polypeptidesVIP, PACAP38, GLP-1, EXENDIN-4 and examples of R3 selectivepolypeptides. Conserved residues are bolded and shaded in dark graywhile conservative changes are shaded in light gray.

FIG. 3 is a restriction map of a typical plasmid containing theGST-peptide fusion.

FIGS. 4A-4B are graphs showing the effects of GLP-1 or R3P3 on insulinrelease from rat islets in vitro.

FIG. 5 is a graph showing the R3P3 peptide effect on glucose disposal.

FIG. 6 is a bar chart showing the effect of PACAP and relatedpolypeptides on intestinal water content of Balb/C mice.

FIG. 7 is a bar chart showing that 1 nmole/kg dose of R3P3, R3P12,R3P13, or GLP-1 enhance glucose disposal in the rat by subcutaneousroute of administration.

FIG. 8A through FIG. 8K depict polynucleotide sequences SEQ ID NOs 54through 56 and 203 through 301 that encode for the polypeptides of thisinvention.

The first 6 nucleotides represent the Bam HI restriction enzymerecognition site followed by the next 12 nucleotides which encode the“IEGR” Factor Xa recognition site. The last 6 nucleotides represent theXho I or Eco RI restriction enzyme recognition site preceded by the 6nucleotides that encode the two stop codons. The nucleotides between theFactor Xa site and stop codons encode the amino acid sequence of thecorresponding polypeptide. The nucleotides between the two restrictionsites are cloned into the corresponding restriction sites on thepGEX-6P-1 vector (Amershm Pharmacia Biotech). The SEQ ID NOs are denotedin parenthesis.

FIG. 9 shows the effect of PACAP-27, VIP and receptor selective agonistson the heart rate in conscious dogs (see example 15).

FIG. 10 shows detection of R3P66 by polyclonal antibodies produced inrabbits immunized with R3P66 C-terminus sequence(Ac-CRKQVMKKYLQSIKNKRY-COOH) (SEQ ID NO: 342), using ELISA.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

This invention provides novel polypeptides, and fragments, derivativesand variants thereof that demonstrate at least one biological functionthat is substantially the same as the polypeptides of FIG. 1(collectively, polypeptides of this invention). The polypeptides of thisinvention function in vivo as R3 agonists or otherwise in the preventionand/or treatment of such diseases or conditions as diabetes, asthma,hypertension, male reproduction problems including human sperm motility,cardiovascular diseases, ulcers, and other conditions identified herein,or function otherwise as described later herein. Preferably, thepolypeptides of this invention will stimulate insulin release frompancreatic beta cells in a glucose-dependent fashion.

The polypeptides of this invention are R3 agonists. Preferably, they areselective R3 agonists with at least 10-fold selectivity for R3 over R2and/or R1. More preferably, they are selective R3 agonists with at least100-fold selectivity for R3 over R2 and/or R1. Most preferably, theystimulate insulin release into plasma in a glucose-dependent fashionwithout inducing a stasis or increase in the level of plasma glucosethat is counterproductive to the treatment of, for example, type 2diabetes. Additionally, it is preferable for the polypeptides of thisinvention to be selective agonists of the R3 receptor, thereby causing,for example, an increase in insulin release into plasma, while beingselective against other receptors that are responsible for suchdisagreeable or dangerous side effects as gastrointestinal waterretention, and/or unwanted cardiovascular effects such as increasedheart rate. It has now been discovered that R3-mediated insulinsecretion does not cause hypoglycemia, R2 activation leads to glucoserelease into plasma which is counterproductive to the treatment of type2 diabetes and gastrointestinal water retention, and R1 activation leadsto cardiovascular effects such as increased heart rate.

The polypeptides of this invention provide a new therapy for patientswith decreased endogenous insulin secretion or impaired glucosetolerance in particular type 2 diabetes.

A. Discussion

PACAP, VIP, GLP-1 and Exendin-4 are polypeptides capable of stimulatinginsulin release in a glucose-dependent fashion. However, this fact alonedoes not guarantee glucose reduction in vivo. Since PACAP is known tobind to PACAP-R1-R2 and -R3 receptors, and VIP is known to bind toPACAP-R2 and -R3 receptors, it was thought that they may have similarconserved structural features. The stacking alignment below shows theprimary structural relationships:

SEQ ID NO. VIP 1 HSDAVFTDNY TRLRKQMAVK KYLNSILN-NH₂ 28 1 PACAP38 1HSDGIFTDSY SRYRKQMAVK KYLAAVLGKR YKQRVKNK-NH₂ 38 2 GLP-1 1 HAEGTFTSDVSSYLEGQAAK EFIAWLVKGR-NH₂ 30 3 Exendin 4 1 HGEGTFTSDL SKQMEEEAVRLFIEWLKNGG PSSGAPPPS-NH₂ 39 4(where single-letter abbreviations for amino acids can be found inZubay, Biochemistry 2d ed., 1988, MacMillan Publishing, New York, p.33), and are defined below. The polypeptides of the present invention(FIG. 1) are most closely related to VIP in terms of their primarystructure with the exception of SEQ ID NO: 57-61, 66-69, and 176, 177,179, 180, 183-202 which are more closely related to PACAP.

The inventors herein have created a new polypeptide that is an R3agonist, preferably a selective R3 agonist, and/or that exhibits aselective glucose-dependent insulin secretagogue effect whereinselective activation of the PACAP R3 receptor indeed leads to a glucosedependent pathway to insulin secretion by pancreatic beta cells, withconcomitant glucose reduction in vivo. In that light, they first studiedthe structures of PACAP-27 and VIP in an effort to determine theresidues most likely responsible for receptor selectivity. It is knownthat PACAP and VIP do not reduce glucose in vivo, but, rather, theystimulate glucose release from the liver. It has been shown thatactivation of R2 increases plasma glucose levels in vivo. Previously,both PACAP and VIP have been mutagenized extensively for variousreasons. For instance, serial deletions of PACAP27 and PACAP38 from bothends confirmed the importance of both termini for receptor binding(Gourlet et al., Eur. J. Pharm. 287: 7-11, (1995); Gourlet et al.,Regul. Peptides 62: 125-130, (1996)). Rat brain membrane binding andadenylate cyclase activities of PACAP27/VIP hybrid muteins implicatedthe importance of the N-terminal residues of PACAP for PACAP-R1recognition (Ando et al., Biomed. Pept. Proteins Nucleic Acids 2:41-46,(1996)). Increasing the basicity of Leu¹⁷-PACAP27 and Leu¹⁷-VIP bymaking K15R, K20R, and K21R mutations and extension of the C-terminuswith “GKR” sequence led to an increase in duration of guinea pigtracheal relaxant activity proposed to be due to protection from heparinbinding (Kashimoto et al., Ann. NY Acad. Sci. 805: 505-510, (1996)).Gourlet et al. (Biochim. Biophys. Acta 1314: 267-273, (1996))demonstrated that the Q16R mutein of VIP and PACAP possessed greateraffinities than their respective native polypeptides for PACAP-R2 andR1, respectively. Gourlet et al. (Peptides 18: 1539-1545, (1997))developed a high affinity R2-selective agonist by making the chimericsubstituted peptide [K15, R16, L27] VIP(1-7)/GRF(8-27). N-terminalacylation and D-Phe2 substitution of this selective agonist led to apotent R2 selective antagonist (Gourlet et al., Peptides 18 1555-1560,(1997)). VIP muteins Y22L and Y22A, but not Y22F, display lower affinityfor PACAP-R3, suggesting the importance of an aromatic group at position22 for receptor R3 binding but not for receptor R2 binding (Gourlet,Eur. J. Biochem. 348: 95-99, (1998)). Helodermin and helospectin,VIP-like peptides isolated from the salivary gland venom of lizardsexhibit ˜100-fold PACAP-R3 selectivity (Gourlet, Ann. NY Acad. Sci. 865:247-252, (1998)). Photoaffinity labeling of PACAP27 by replacing F6 andY22 with p-benzoyl-L-phenylalanine (pBz) or K15, K20, and K21 with pBz₂suggested that K15 and F22 are closer to PACAP-R1 than F6, K20, and K21(Cao et al., Eur. J. Biochem. 244: 400-406, (1997); Cao et al., Ann. NYAcad. Sci., 865: 82-91, (1998)).

The inventors herein have found several polypeptides that cause thestimulation of release of insulin in a glucose-dependent manner andcause glucose reduction in vivo. Those polypeptides bear some similarityto VIP and PACAP. In particular, a stacked alignment shows thefollowing:

SEQ. ID NO. VIP 1 HSDAVFTDNY TRLRKQMAVK KYLNSILN-NH₂ 28 1 PACAP38 1HSDGIFTDSY SRYRKQMAVK KYLAAVLGKR YKQRVKNK-NH₂ 38 2 R3P1 Ac-HSDAVFTENYTKLRKQLAAK KYLNDLKKGG T-NH₂ 31 6 R3P3 1 HSDAVFTENY TKLRKQLAAK KYLNDLKKGGT 31 8 R3P12 1 HSDAVFTDNY TRLRKQLAAK KYLNDIKKGG T 31 15 R3P13 1HSDAVFTDNY TRLRKQLAAK KYLNDIKK-NH₂ 28 16 R3P36 1 HSDAVFTDNY TRLRKQLAAKKYLNDIKKKR Y 31 32 R3P66 1 HSDAVFTDNY TRLRKQVAAK KYLQSIKNKR Y 31 72However, there is no teaching in the scientific or patent literaturethat suggests that select modifications to the VIP and PACAP sequenceslead to a polypeptide with the ability to stimulate insulin secretion ina glucose-dependent fashion, and reduce plasma glucose concentration.

Certain terms used throughout this specification will now be defined,and others will be defined as introduced. The single letter abbreviationfor a particular amino acid, its corresponding amino acid, and threeletter abbreviation are as follows: A, alanine (ala); C, cysteine (cys);D, aspartic acid (asp); E, glutamic acid (glu); F, phenylalanine (phe);G, glycine (gly); H, histidine (his); I, isoleucine (ile); K, lycine(lys); L, leucine (leu); M, methionine (met); N, asparagine (asn); P,proline (pro); Q, glutamine (gin); R, arginine (arg); S, serine (ser);T, threonine (thr); V, valine (val); W, tryptophan (trp); Y, tyrosine(tyr).

The term “polynucleotide encoding a polypeptide” encompasses apolynucleotide which includes only coding sequence for the polypeptideas well as a polynucleotide which includes additional coding and/ornon-coding sequence. The present invention further relates topolynucleotides which hybridize to the hereinabove-described sequencesif there is at least about 70%, preferably at least about 90%, and morepreferably at least about 95% identity between the sequences. Thepresent invention particularly relates to polynucleotides encodingpolypeptides which hybridize under stringent conditions to thehereinabove-described polynucleotides. As herein used, the term“stringent conditions” means “stringent hybridization conditions”Preferably, hybridization will occur only if there is at least about 90%and preferably about 95% through 97% identity between the sequences. Thepolynucleotides which hybridize to the hereinabove describedpolynucleotides in a preferred embodiment encode polypeptides whichretain substantially the same biological function or activity as themature polypeptide encoded by the cDNAs.

“Functional equivalent” and “substantially the same biological functionor activity” each means that degree of biological activity that iswithin about 30% to 100% or more of that biological activitydemonstrated by the polypeptide to which it is being compared when thebiological activity of each polypeptide is determined by the sameprocedure. For example, a polypeptide that is functionally equivalent toa polypeptide of FIG. 1 is one that, when tested in the Cyclic AMPscintillation proximity assay of Specific Example 16, demonstratesaccumulation of cAMP in CHO cell line expressing the human PACAP/VIP R2(PACAP R3) receptor.

A polypeptide of this invention that is an R3 agonist is one thatdemonstrates about 30% -100% or more of maximal PACAP-27 R3 agonistactivity when tested in the protocol of Example 16. The preferredpolypeptides of this invention that are selective agonists for R3 overPACAP R2 and R1 receptors are those polypeptides that demonstrate theratio of R3 agonist activity to R2 activity of about 10:1 or greater,and more preferably, about 100:1 or greater, and/or demonstrate theratio of R3 agonist activity to R1 receptor activity of about 10:1 orgreater, and more preferably, about 100:1 or greater when thepolypeptide is tested in the protocol of Example 16, using cells thatexpress the appropriate receptors.

“Stringent hybridization conditions” refers to an overnight incubationof the two pieces of polynucleotides to be hybridized at 42° C. in asolution comprising 50% formamide, 5×SSC (750 mM NaCl, 75 mM sodiumcitrate), 50 mM sodium phosphate (pH 7.6), 5× Denhardt's solution, 10%dextran sulfate, and 20 μg/ml denatured, sheared salmon sperm DNA,followed by washing the filters in 0.1×SSC at about 65° C.

The terms “fragment,” “derivative”, and “variant”, when referring to thepolypeptides of FIG. 1, means fragments, derivatives, and variants ofthe polypeptides which retain substantially the same biological functionor activity as such polypeptides, as described further below.

An analog includes a propolypeptide which includes within it, the aminoacid sequence of the polypeptide of this invention. The activepolypeptide of this invention can be cleaved from the additional aminoacids that complete the propolypeptide molecule by natural, in vivoprocesses or by procedures well known in the art such as by enzymatic orchemical cleavage. For example, the 28-amino acid native peptide VIP isnaturally expressed as a much larger polypeptide which is then processedin vivo to release the 28-amino acid active mature peptide.

A fragment is a portion of the polypeptide which retains substantiallysimilar functional activity, as shown in the in vivo models disclosedherein as described further below.

A derivative includes all modifications to the polypeptide whichsubstantially preserve the functions disclosed herein and includeadditional structure and attendant function, e.g., PEGylatedpolypeptides which have greater half-life, fusion polypeptides whichconfer targeting specificity or an additional activity such as toxicityto an intended target, as described further below.

The polypeptides of the present invention may be recombinantpolypeptides, natural purified polypeptides or synthetic polypeptides.

The fragment, derivative, or variant of the polypeptides of the presentinvention may be (i) one in which one or more of the amino acid residuesare substituted with a conserved or non-conserved amino acid residue(preferably a conserved amino acid residue) and such substituted aminoacid residue may or may not be one encoded by the genetic code, or (ii)one in which one or more of the amino acid residues includes asubstituent group, or (iii) one in which the mature polypeptide is fusedwith another compound, such as a compound to increase the half-life ofthe polypeptide (for example, polyethyleneglycol), or (iv) one in whichthe additional amino acids are fused to the mature polypeptide, such asa leader or secretory sequence or a sequence which is employed forpurification of the mature polypeptide or a propolypeptide sequence, orv) one in which the polypeptide sequence is fused with a largerpolypeptide, i.e. human albumin, a antibody or Fc, for increasedduration of effect. Such fragments, derivatives, and variants andanalogs are deemed to be within the scope of those skilled in the artfrom the teachings herein.

Preferably, the derivatives of the present invention will containconservative amino acid substitutions (defined further below) made atone or more predicted, preferably nonessential amino acid residues. A“nonessential” amino acid residue is a residue that can be altered fromthe wild-type sequence of a protein without altering the biologicalactivity, whereas an “essential” amino acid residue is required forbiological activity. A “conservative amino acid substitution” is one inwhich the amino acid residue is replaced with an amino acid residuehaving a similar side chain. Families of amino acid residues havingsimilar side chains have been defined in the art. These families includeamino acids with basic side chains (e.g., lysine, arginine, histidine),acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polarside chains (e.g., glycine, asparagine, glutamine, serine, threonine,tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine,leucine, isoleucine, proline, phenylalanine, methionine, tryptophan),beta-branched side chains (e.g., threonine, valine, isoleucine) andaromatic side chains (e.g., tyrosine, phenylalanine, tryptophan,histidine). Non conservative substitutions would not be made forconserved amino acid residues or for amino acid residues residing withina conserved protein domain, such as residues 19 and 27 where suchresidues are essential for protein activity such as R3 activity and/orR3 selectivity. Fragments, or biologically active portions includepolypeptide fragments suitable for use as a medicament, to generateantibodies, as a research reagent, and the like. Fragments includepeptides comprising amino acid sequences sufficiently similar to orderived from the amino acid sequences of a polypeptide of this inventionand exhibiting at least one activity of that polypeptide, but whichinclude fewer amino acids than the full-length polypeptides disclosedherein. Typically, biologically active portions comprise a domain ormotif with at least one activity of the polypeptide. A biologicallyactive portion of a polypeptide can be a peptide which is, for example,5 or more amino acids in length. Such biologically active portions canbe prepared synthetically or by recombinant techniques and can beevaluated for one or more of the functional activities of a polypeptideof this invention by means disclosed herein and/or well known in theart.

Moreover, preferred derivatives of the present invention include maturepolypeptides that have been fused with another compound, such as acompound to increase the half-life of the polypeptide and/or to reducepotential immunogenicity of the polypeptide (for example,polyethyleneglycol “PEG”). In the case of PEGylation, the fusion of thepolypeptide to PEG can be accomplished by any means known to one skilledin the art. For example, PEGylation can be accomplished by firstintroducing a cysteine mutation into the polypeptide, followed bysite-specific derivatization with PEG-maleimide. The cysteine can beadded to the C-terminus of the peptides. (See, for instance, Tsutsumi etal., Proc Natl Acad Sci U S A 2000 Jul. 18;97(15):8548-53).

Variants of the polypeptides of this invention include polypeptideshaving an amino acid sequence sufficiently similar to the amino acidsequence of the SEQ ID NOs of FIG. 1 or a domain thereof. The term“sufficiently similar” means a first amino acid sequence that contains asufficient or minimum number of identical or equivalent amino acidresidues relative to a second amino acid sequence such that the firstand second amino acid sequences have a common structural domain and/orcommon functional activity. For example, amino acid sequences thatcontain a common structural domain that is at least about 45%,preferably about 75% through 98%, identical are defined herein assufficiently similar. Preferably, variants will be sufficiently similarto the amino acid sequence of the preferred polypeptides of thisinvention. Variants include variants of polypeptides encoded by apolynucleotide that hybridizes to a polynucleotide of this invention ora complement thereof under stringent conditions. Such variants generallyretain the functional activity of the polypeptides of this invention.Libraries of fragments of the polynucleotides can be used to generate avariegated population of fragments for screening and subsequentselection. For example, a library of fragments can be generated bytreating a double-stranded PCR fragment of a polynucleotide with anuclease under conditions wherein nicking occurs only about once permolecule, denaturing the double-stranded DNA, renaturing the DNA to formdouble-stranded DNA which can include sense/antisense pairs fromdifferent nicked products, removing single-stranded portions fromreformed duplexes by treatment with S1 nuclease, and ligating theresulting fragment library into an expression vector. By this method,one can derive an expression library that encodes N-terminal andinternal fragments of various sizes of the polypeptide of thisinvention.

Variants include polypeptides that differ in amino acid sequence due tomutagenesis. Variants that function as R3 agonists can be identified byscreening combinatorial libraries of mutants, for example truncationmutants, of the polypeptides of this invention for R3 agonist activity.

In one embodiment, a variegated library of analogs is generated bycombinatorial mutagenesis at the nucleic acid level and is encoded by avariegated gene library. A variegated library of variants can beproduced by, for example, enzymatically ligating a mixture of syntheticoligonucleotides into gene sequences such that a degenerate set ofpotential variant amino acid sequences is expressible as individualpolypeptides, or, alternatively, as a set of larger fusion proteins (forexample, for phage display) containing the set of sequences therein.There are a variety of methods that can be used to produce libraries ofpotential variants from a degenerate oligonucleotide sequence. Chemicalsynthesis of a degenerate gene sequence can be performed in an automaticDNA synthesizer, and the synthetic gene then ligated into an appropriateexpression vector. Use of a degenerate set of genes allows for theprovision, in one mixture, of all of the sequences encoding the desiredset of potential variant sequences. Methods for synthesizing degenerateoligonucleotides are known in the art (see, e.g., Narang (1983)Tetrahedron 39:3; Itakura et al (1984) Annu. Rev. Biochem. 53:323;Itakura et al (1984) Science 198:1056; Ike et al (1983) Nucleic AcidRes. 11:477).

Several techniques are known in the art for screening gene products ofcombinatorial libraries made by point mutations or truncation and forscreening cDNA libraries for gene products having a selected property.Such techniques are adaptable for rapid screening of the gene librariesgenerated by the combinatorial mutagenesis of R-agonist polypeptides.The most widely used techniques, which are amenable to high through-putanalysis for screening large gene libraries typically include cloningthe gene library into replicable expression vectors, transformingappropriate cells with the resulting library of vectors and expressingthe combinatorial genes under conditions in which detection of a desiredactivity facilitates isolation of the vector encoding the gene whoseproduct was detected. Recursive ensemble mutagenesis (REM), a techniquethat enhances the frequency of functional mutants in the libraries, canbe used in combination with the screening assays to identify the desiredvariants.

The invention also provides chimeric or fusion polypeptides. Examplesinclude those polypeptides of this invention described in SEQ ID NOs 18and 172 which are fusions of the pancreatic targeting sequence“SWCEPGWCR” (SEQ ID NO: 343) (Rajotte D., et al (1998) J Clin Invest102:430437) with SEQ ID NOs 8 and 32, respectively. The targetingsequence is designed to localize the delivery of the polypeptide to thepancreas to minimize potential side effects. The polypeptides of thisinvention can be composed of amino acids joined to each other by peptidebonds or modified peptide bonds, i.e., peptide isosteres, and maycontain amino acids other than the 20 gene-encoded amino acids. Thepolypeptides may be modified by either natural processes, such asposttranslational processing, or by chemical modification techniqueswhich are well known in the art. Such modifications are well describedin basic texts and in more detailed monographs, as well as in avoluminous research literature. Modifications can occur anywhere in apolypeptide, including the peptide backbone, the amino acid side-chainsand the amino or carboxyl termini. It will be appreciated that the sametype of modification may be present in the same or varying degrees atseveral sites in a given polypeptide. Also, a given polypeptide maycontain many types of modifications. Polypeptides may be branched, forexample, as a result of ubiquitination, and they may be cyclic, with orwithout branching. Cyclic, branched, and branched cyclic polypeptidesmay result from posttranslation natural processes or may be made bysynthetic methods. Modifications include acetylation, acylation,ADP-ribosylation, amidation, covalent attachment of flavin, covalentattachment of a heme moiety, covalent attachment of a nucleotide ornucleotide derivative, covalent attachment of a lipid or lipidderivative, covalent attachment of phosphotidylinositol, cross-linking,cyclization, disulfide bond formation, demethylation, formation ofcovalent cross-links, formation of cysteine, formation of pyroglutamate,formulation, gamma-carboxylation, glycosylation, GPI anchor formation,hydroxylation, iodination, methylation, myristoylation, oxidation,pegylation, proteolytic processing, phosphorylation, prenylation,racemization, selenoylation, sulfation, transfer-RNA mediated additionof amino acids to proteins such as arginylation, and ubiquitination.(See, for instance, Proteins, Structure and Molecular Properties, 2nded., T. E. Creighton, W. H. Freeman and Company, New York (1993);Posttranslational Covalent Modification of Proteins, B. C. Johnson, ed.,Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth.Enzymol 182:626-646 (1990); Rattan et al., Ann. N.Y. Acad. Sci.663:48-62 (1992)).

The polypeptides of the present invention include the polypeptides ofFIG. 1, that are SEQ ID NOs: 11 through 14, SEQ ID NO: 18, SEQ ID NOs:21 through 26, SEQ ID NOs: 32 through 36, SEQ ID NOs: 40 through 53, SEQID NOs: 57 through 61, SEQ ID NOs: 63 through 99, SEQ ID NOs: 102through 119, SEQ ID NOs: 121 through 137, SEQ ID NOs: 139 through 177,SEQ ID NOs: 179, 180, SEQ ID NOs: 183 through 202, 322 through 341, aswell as those sequences having insubstantial variations in sequence fromthem. An “insubstantial variation” would include any sequence,substitution, or deletion variant that maintains substantially at leastone biological function of the polypeptides of this invention,preferably R3 agonist activity, and more preferably selective R3 agonistactivity, and most preferably, the insulin secreting activitydemonstrated herein. These functional equivalents may preferably includepolypeptides which have at least about a 90% identity to thepolypeptides of FIG. 1, and more preferably at least a 95% identity tothe polypeptides of FIG. 1, and still more preferably at least a 97%identity to the polypeptides of FIG. 1, and also include portions ofsuch polypeptides having substantially the same biological activity.However, any polypeptide having insubstantial variation in amino acidsequence from the polypeptides of FIG. 1 that demonstrates functionalequivalency as described further herein is included in the descriptionof the present invention.

As known in the art “similarity” between two polypeptides is determinedby comparing the amino acid sequence and its conserved amino acidsubstitutes of one polypeptide to the sequence of a second polypeptide.Such conservative substitutions include those described above and byDayhoff in The Atlas of Protein Sequence and Structure 5 (1978), and byArgos in EMBO J., 8:779-785 (1989). For example, amino acids belongingto one of the following groups represent conservative changes:

-   -   ala, pro, gly, gln, asn, ser, thr;    -   cys, ser, tyr, thr;    -   val, ile, leu, met, ala, phe;    -   lys, arg, his;    -   phe, tyr, trp, his; and    -   asp, glu.

The present invention also relates to vectors which includepolynucleotides of the present invention, host cells which aregenetically engineered with vectors of the invention and the productionof polypeptides of the invention by recombinant techniques. Host cellsmay be genetically engineered (transduced or transformed or transfected)with the vectors of this invention which may be, for example, a cloningvector or an expression vector. The vector may be, for example, in theform of a plasmid, a viral particle, a phage, etc. The engineered hostcells can be cultured in conventional nutrient media modified asappropriate for activating promoters, or selecting transformants. Theculture conditions, such as temperature, pH and the like, are thosepreviously used with the host cell selected for expression, and will beapparent to the ordinarily skilled artisan. The polynucleotide of thepresent invention may be employed for producing a polypeptide byrecombinant techniques. Thus, for example, the polynucleotide sequencemay be included in any one of a variety of expression vehicles, inparticular vectors or plasmids for expressing a polypeptide. Suchvectors include chromosomal, non-chromosomal and synthetic DNAsequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA;yeast plasmids; vectors derived from combinations of plasmids and phageDNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, andpseudorabies. However, any other vector or plasmid may be used as longas they are replicable and viable in the host.

The appropriate DNA sequence may be inserted into the vector by avariety of procedures. In general, the DNA sequence is inserted into anappropriate restriction endonuclease site by procedures known in theart. Such procedures and others are deemed to be within the scope ofthose skilled in the art. The DNA sequence in the expression vector isoperatively linked to an appropriate expression control sequence(s)(promoter) to direct mRNA synthesis. As representative examples of suchpromoters, there may be mentioned: LTR or SV40 promoter, the E. coli.lac or trp, the phage lambda P_(L) promoter and other promoters known tocontrol expression of genes in prokaryotic or eukaryotic cells or theirviruses. The expression vector also contains a ribosome binding site fortranslation initiation and a transcription terminator. The vector mayalso include appropriate sequences for amplifying expression. Inaddition, the expression vectors preferably contain a gene to provide aphenotypic trait for selection of transformed host cells such asdihydrofolate reductase or neomycin resistance for eukaryotic cellculture, or such as tetracycline or ampicillin resistance in E. coli.The vector containing the appropriate DNA sequence as herein abovedescribed, as well as an appropriate promoter or control sequence, maybe employed to transform an appropriate host to permit the host toexpress the protein. As representative examples of appropriate hosts,there may be mentioned: bacterial cells, such as E. coli, Salmonellatyphimurium, Streptomyces; fungal cells, such as yeast; insect cells,such as Drosophila S2 and Spodoptera Sf9; animal cells such as CHO, COSor Bowes melanoma; adenoviruses; plant cells, etc. The selection of anappropriate host is deemed to be within the scope of those skilled inthe art from the teachings herein.

The present invention also includes recombinant constructs comprisingone or more of the sequences as broadly described above. The constructscomprise a vector, such as a plasmid or viral vector, into which asequence of the invention has been inserted, in a forward or reverseorientation. In a preferred aspect of this embodiment, the constructfurther comprises regulatory sequences, including, for example, apromoter, operably linked to the sequence. Large numbers of suitablevectors and promoters are known to those of skill in the art, and arecommercially available. The following vectors are provided by way ofexample. Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pBS, phagescript,psiX174, pBluescript SK, pBsKS, pNH8a, pNH16a, pNH18a, pNH46a(Stratagene); pTRC99A, pKK223-3, pKK233-3, pDR540, PRIT5 (Pharmacia).Eukaryotic: pWLneo, pSV2cat, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV,pMSG, PSVL (Pharmacia). However, any other plasmid or vector may be usedas long as they are replicable and viable in the host. Promoter regionscan be selected from any desired gene using CAT(chloramphenicoltransferase) vectors or other vectors with selectable markers. Twoappropriate vectors are pKK232-8 and pCM7. Particular named bacterialpromoters include laci, lacZ, T3, T7, gpt, lambda P_(R), P_(L) and trp.Eukaryotic promoters include CMV immediate early, HSV thymidine kinase,early and late SV40, LTRs from retrovirus, and mouse metallothionein-I.Selection of the appropriate vector and promoter is well within thelevel of ordinary skill in the art.

The present invention also relates to host cells containing theabove-described construct. The host cell can be a higher eukaryoticcell, such as a mammalian cell, or a lower eukaryotic cell, such as ayeast cell, or the host cell can be a prokaryotic cell, such as abacterial cell. Introduction of the construct into the host cell can beeffected by calcium phosphate transfection, DEAE-Dextran mediatedtransfection, or electroporation (Davis, L., Dibner, M., Battey, I.,Basic Methods in Molecular Biology, (1986)). The constructs in hostcells can be used in a conventional manner to produce the gene productencoded by the recombinant sequence. Alternatively, the polypeptides ofthe invention can be synthetically produced by conventional peptidesynthesizers.

Mature proteins can be expressed in mammalian cells, yeast, bacteria, orother cells under the control of appropriate promoters. Cell-freetranslation systems can also be employed to produce such proteins usingRNAs derived from the DNA constructs of the present invention.Appropriate cloning and expression vectors for use with prokaryotic andeukaryotic hosts are described by Sambrook, et al., Molecular Cloning: ALaboratory Manual, Second Edition, (Cold Spring Harbor, N.Y., 1989), thedisclosure of which is hereby incorporated by reference.

Transcription of a DNA encoding the polypeptides of the presentinvention by higher eukaryotes is increased by inserting an enhancersequence into the vector. Enhancers are cis-acting elements of DNA,usually from about 10 to 300 bp, that act on a promoter to increase itstranscription. Examples include the SV40 enhancer on the late side ofthe replication origin (bp 100 to 270), a cytomegalovirus early promoterenhancer, a polyoma enhancer on the late side of the replication origin,and adenovirus enhancers. Generally, recombinant expression vectors willinclude origins of replication and selectable markers permittingtransformation of the host cell, e.g., the ampicillin resistance gene ofE. coli and S. cerevisiae TRP1 gene, and a promoter derived from ahighly-expressed gene to direct transcription of a downstream structuralsequence. Such promoters can be derived from operons encoding glycolyticenzymes such as 3-phosphoglycerate kinase (PGK), α factor, acidphosphatase, or heat shock proteins, among others. The heterologousstructural sequence is assembled in appropriate phase with translation,initiation and termination sequences, and preferably, a leader sequencecapable of directing secretion of translated protein into theperiplasmic space or extracellular medium. Optionally, the heterologoussequence can encode a fusion protein including an N-terminalidentification peptide imparting desired characteristics, e.g.,stabilization or simplified purification of expressed recombinantproduct.

Useful expression vectors for bacterial use are constructed by insertinga structural DNA sequence encoding a desired protein together withsuitable translation, initiation and termination signals in operablereading phase with a functional promoter. The vector will comprise oneor more phenotypic selectable markers and an origin of replication toensure maintenance of the vector and to, if desirable, provideamplification within the host. Suitable prokaryotic hosts fortransformation include E.coli, Bacillus subtilis, Salmonella typhimuriumand various species within the genera Pseudomonas, Streptomyces, andStaphylococcus, although others may also be employed as a matter ofchoice. Useful expression vectors for bacterial use can comprise aselectable marker and bacterial origin of replication derived fromcommercially available plasmids comprising genetic elements of the wellknown cloning vector pBR322 (ATCC 37017). Such commercial vectorsinclude, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala,Sweden) and GEM1 (Promega Biotec, Madison, Wis., USA). These pBR322“backbone” sections are combined with an appropriate promoter and thestructural sequence to be expressed.

After transformation of a suitable host strain and growth of the hoststrain to an appropriate cell density, the selected promoter isderepressed by appropriate means (e.g., temperature shift or chemicalinduction) and cells are cultured for an additional period. Cells aretypically harvested by centrifugation, disrupted by physical or chemicalmeans, and the resulting crude extract retained for furtherpurification. Microbial cells employed in expression of proteins can bedisrupted by any convenient method, including freeze-thaw cycling,sonication, mechanical disruption, or use of cell lysing agents.

Various mammalian cell culture systems can also be employed to expressrecombinant protein. Examples of mammalian expression systems includethe COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell23:175 (1981), and other cell lines capable of expressing a compatiblevector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines.Mammalian expression vectors will comprise an origin of replication, asuitable promoter and enhancer, and also any necessary ribosome bindingsites, polyadenylation site, splice donor and acceptor sites,transcriptional termination sequences, and 5′ flanking nontranscribedsequences. DNA sequences derived from the SV40 viral genome, forexample, SV40 origin, early promoter, enhancer, splice, andpolyadenylation sites may be used to provide the requirednon-transcribed genetic elements.

The polypeptides of the present invention may be recovered and purifiedfrom recombinant cell cultures by methods used heretofore, includingammonium sulfate or ethanol precipitation, acid extraction, anion orcation exchange chromatography, phosphocellulose chromatography,hydrophobic interaction chromatography, affinity chromatography,hydroxyapatite chromatography and lectin chromatography. Proteinrefolding steps can be used, as necessary, in completing configurationof the mature protein. Finally, high performance liquid chromatography(HPLC) can be employed for final purification steps.

The polypeptides of this invention may be a product of chemicalsynthetic-procedures, or produced by recombinant techniques from aprokaryotic or eukaryotic host (for example, by bacterial, yeast, higherplant, insect and mammalian cells in culture). Depending upon the hostemployed in a recombinant production procedure, the polypeptides of thisinvention may be glycosylated with mammalian or other eukaryoticcarbohydrates or may be non-glycosylated. Polypeptides of this inventionmay also include an initial methionine amino acid residue. An isolatedor purified polypeptide of this invention, or biologically activeportion thereof, is substantially free of other cellular material, orculture medium when produced by recombinant techniques, or substantiallyfree of chemical precursors or other chemicals when chemicallysynthesized. Preferably, an isolated polypeptide of this invention issubstantially free of cellular material and has less than about 30% (bydry weight) of non-polypeptide, or contaminating, material. When thepolypeptide of this invention or a biologically active portion thereofis recombinantly produced, preferably culture medium represents lessthan about 30% of the volume of the polypeptide preparation. When thisinvention is produced by chemical synthesis, preferably the preparationscontain less than about 30% by dry weight of chemical precursors ornon-invention chemicals.

The polypeptides of this invention can be conveniently isolated asdescribed in the specific examples below. A preparation of purifiedpolypeptide is at least about 70% pure; preferably, the preparations are85% through 99% pure. Purity of the preparations can be assessed by anymeans known in the art, such as SDS-polyacrylamide gel electrophoresisand Mass Spec/Liquid Chromatography.

Polynucleotide sequences encoding a polypeptide of this invention can besynthesized, in whole or in part, using chemical methods well known inthe art (see, for example, Caruthers et al, Nucl. Acids Res. Symp. Ser.215-223, 1980; Horn et al, Nucl. Acids Res. Symp.Ser 225-232, 1980). Thepolynucleotide that encodes the polypeptide can then be cloned into anexpression vector to express the polypeptide.

As will be understood by those of skill in the art, it may beadvantageous to produce the polypeptide-encoding nucleotide sequencespossessing non-naturally occurring codons. For example, codons preferredby a particular prokaryotic or eukaryotic host can be selected toincrease the rate of polypeptide expression or to produce an RNAtranscript having desirable properties, such as a half-life which islonger than that of a transcript generated from the naturally occurringsequence.

The nucleotide sequences disclosed herein can be engineered usingmethods generally known in the art to alter the polypeptide-encodingsequences for a variety of reasons, including but not limited to,alterations which modify the closing, processing, and/or expression ofthe polypeptide or mRNA product. DNA shuffling by random fragmentationand PCR reassembly of gene fragments and synthetic oligonucleotides canbe used to engineer the nucleotide sequences. For example, site-directedmutagenesis can be used to insert new restriction sites, alterglycosylation patterns, change codon preference, produce splicevariants, introduce mutations, and so forth.

Alternatively, the polypeptides of this invention can be produced usingchemical methods to synthesize its amino acid sequence, such as bydirect peptide synthesis using solid-phase techniques (see, for example,Merrifield, J. Am. Chem. Soc. 85, 2149-2154, 1963; Roberge et al,Science, 269, 202-204, 1995). Polypeptide synthesis can be performedusing manual techniques or by automation. Automated synthesis can beachieved, for example, using Applied Biosystems 431A Peptide Synthesizer(Perkin Elmer). Optionally, fragments of the polypeptide can beseparately synthesized and combined using chemical methods to produce afull-length molecule.

The newly synthesized polypeptide can be substantially purified bypreparative high performance liquid chromatography (see, for example,Creighton, PROTEINS: STRUCTURES AND MOLECULAR PRINCILPLES, WH Freemanand Co., New York, N.Y., 1983). The composition of a syntheticpolypeptide of the present invention can be confirmed by amino acidanalysis or sequencing by, for example, the Edman degradation procedure(see, Creighton, supra). Additionally, any portion of the amino acidsequence of the polypeptide can be altered during direct synthesisand/or combined using chemical methods with sequences from otherproteins to produce a variant polypeptide or a fusion polypeptide.

The polypeptides of the present invention, as a result of the ability tostimulate insulin secretion from pancreatic islet cells in vitro, and bycausing a decrease in blood glucose in vivo, may be employed intreatment of type 2 Diabetes (non-insulin dependent diabetes mellitus).Also, the polypeptides may be used to prevent subjects with impairedglucose tolerance from proceeding to develop type 2 diabetes. Inaddition, the polypeptides of the invention may be used for treatment ofasthma (Bolin et al Biopolymer 37:57-66 (1995); U.S. Pat. No.5,677,419)(showing that polypeptide R3P0 is active in relaxing guineapig tracheal smooth muscle); hypotension induction (VIP induceshypotension, tachycardia, and facial flushing in asthmatic patients(Morice, A. H., and Sever, P. S., Peptides 7:279-280 (1986); Morice, A.,et al., The Lancet II, 1225-1227 (1983)), male reproduction problems(Siow, Y., et al., Effects of vasoactive intestinal peptide on humansperm motility, Arch. Androl. 1999 July-August; 43(1):67-71); as aanti-apoptosis/neuroprotective agent (Brenneman D. E., et al., VIPneurotrophism in the central nervous system: multiple effectors andidentification of a femtomolar-acting neuroprotective peptide, Ann. N.Y. Acad. Sci. 1998 Dec. 11;865:207-12); cardioprotection during ischemicevents (Kalfin R., et al., Protective role of intracoronary vasoactiveintestinal peptide in ischemic and reperfused myocardium, J. Pharmacol.Exp. Ther. 1994 February;268(2):952-8; Das, D. K., et al., Coordinatedrole of vasoactive intestinal peptide and nitric oxide incardioprotection, Ann. N. Y. Acad. Sci. 1998 Dec. 11 ;865:297-308), andfinally as an anti-ulcer agent (Tuncel, et al., The protective effect ofvasoactive intestinal peptide (VIP) on stress-induced gastric ulcerationin rats, Ann. N. Y. Acad. Sci. 1998 Dec. 11;865:309-22.

The polypeptides of the present invention may be employed in combinationwith a suitable pharmaceutical carrier to comprise a pharmaceuticalcomposition for parenteral administration. Such compositions comprise atherapeutically effective amount of the polypeptide and apharmaceutically acceptable carrier or excipient. Such a carrierincludes but is not limited to saline, buffered saline, dextrose, water,glycerol, ethanol, and combinations thereof. The formulation should suitthe mode of administration. The invention also provides a pharmaceuticalpack or kit comprising one or more containers filled with one or more ofthe ingredients of the pharmaceutical compositions of the invention.Associated with such container(s) can be a notice in the form prescribedby a governmental agency regulating the manufacture, use or sale ofpharmaceuticals or biological products, which notice reflects approvalby the agency of manufacture, use or sale for human administration. Inaddition, the polypeptides of the present invention may be employed inconjunction with other therapeutic compounds.

The pharmaceutical compositions may be administered in a convenientmanner such as by the oral, topical, intravenous, intraperitoneal,intramuscular, subcutaneous, intranasal or intradermal routes. Thepharmaceutical compositions are administered in an amount which iseffective for treating and/or prophylaxis of the specific indication. Ingeneral, they are administered in an amount of at least about 350 ng(0.1 nmol)/kg body weight and in most cases they will be administered inan amount not in excess of about 35 ug (10 nmol)/kg body weight per day.In most cases, the dosage is from about 0.1 μg/kg to about 100 mg/kgbody weight daily, taking into account the routes of administration,symptoms, etc. These numbers do not take into account thebioavailability of the peptide in vivo, in which case more or less maybe used to attain the effective dose desired. One of ordinary skill inthe art is able to determine through dosing experiments or otherconventional means the gross amount to be used to produce an effectivedosage.

A polypeptide of the invention may also be employed in accordance withthe present invention by expression of such polypeptide in vivo, whichis often referred to as “gene therapy.” Thus, for example, cells may beengineered with a polynucleotide (DNA or RNA) encoding for thepolypeptide ex vivo, the engineered cells are then provided to a patientto be treated with the polypeptide. Such methods are well-known in theart. For example, cells may be engineered by procedures known in the artby use of a retroviral particle containing RNA encoding for thepolypeptide of the present invention.

Local delivery of the insulin secretagogues using gene therapy mayprovide the therapeutic agent to the target area, i.e., the pancreas.For instance a pancreas-specific promoter was used to create a beta-cellpancreatic tumor mouse model (Hanahan, D., Heritable formation ofpancreatic beta-cell tumors in transgenic mice expressing recombinantinsulin/simian virus 40 oncogenes, Nature 315(6015):115-22 (1985)).

Both in vitro and in vivo gene therapy methodologies are contemplated.Several methods for transferring potentially therapeutic genes todefined cell populations are known. See, e.g., Mulligan, “The BasicScience Of Gene Therapy”, Science, 260: 926-31 (1993). These methodsinclude:

1) Direct gene transfer. See, e.g., Wolff et al., “Direct Gene transferInto Mouse Muscle In Vivo”, Science, 247:1465-68 (1990);

2) Liposome-mediated DNA transfer. See, e.g., Caplen at al.,“Liposome-mediated CFTR Gene Transfer To The Nasal Epithelium OfPatients With Cystic Fibrosis”, Nature Med. 3: 39-46 (1995); Crystal,“The Gene As A Drug”, Nature Med. 1:15-17 (1995); Gao and Huang, “ANovel Cationic Liposome Reagent For Efficient Transfection Of MammalianCells”, Biochem. Biophys. Res. Comm., 179:280-85 (1991);

3) Retrovirus-mediated DNA transfer. See, e.g., Kay et al., “In VivoGene Therapy Of Hemophilia B: Sustained Partial Correction In FactorIX-Deficient Dogs”, Science, 262:117-19 (1993); Anderson, “Human GeneTherapy”, Science, 256:808-13 (1992).

4) DNA Virus-mediated DNA transfer. Such DNA viruses includeadenoviruses (preferably Ad-2 or Ad-5 based vectors), herpes viruses(preferably herpes simplex virus based vectors), and parvoviruses(preferably “defective” or non-autonomous parvovirus based vectors, morepreferably adeno-associated virus based vectors, most preferably AAV-2based vectors). See, e.g., Ali et al., “The Use Of DNA Viruses AsVectors For Gene Therapy”, Gene Therapy, 1:367-84 (1994); U.S. Pat. No.4,797,368, incorporated herein by reference, and U.S. Pat. No.5,139,941, incorporated herein by reference.

The choice of a particular vector system for transferring the gene ofinterest will depend on a variety of factors. One important factor isthe nature of the target cell population. Although retroviral vectorshave been extensively studied and used in a number of gene therapyapplications, these vectors are generally unsuited for infectingnon-dividing cells. In addition, retroviruses have the potential foroncogenicity. However, recent developments in the field of lentiviralvectors may circumvent some of these limitations. See Naldini et al, Invivo gene delivery and stable transduction of nondividing cells by alentiviral vector, Science 272:263-7 (1996).

Retroviruses from which the retroviral plasmid vectors hereinabovementioned may be derived include, but are not limited to, Moloney MurineLeukemia Virus, spleen necrosis virus, retroviruses such as Rous SarcomaVirus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemiavirus, human immunodeficiency virus, adenovirus, MyeloproliferativeSarcoma Virus, and mammary tumor virus. In one embodiment, theretroviral plasmid vector is derived from Moloney Murine Leukemia Virus.

Adenoviruses have the advantage that they have a broad host range, caninfect quiescent or terminally differentiated cells, such as neurons orhepatocytes, and appear essentially non-oncogenic. See, e.g., Ali etal., supra, p. 367. Adenoviruses do not appear to integrate into thehost genome. Because they exist extrachromosomally, the risk ofinsertional mutagenesis is greatly reduced. Ali et al., supra, p. 373.

Adeno-associated viruses exhibit similar advantages as adenoviral-basedvectors. However, MVs exhibit site-specific integration on humanchromosome 19 (Ali et al., supra, p. 377).

In a preferred embodiment, the DNA encoding the polypeptide insulinsecretagogues of this invention is used in gene therapy for disorderssuch as diabetes.

According to this embodiment, gene therapy with DNA encoding polypeptideinsulin secretagogues or muteins of this invention is provided to apatient in need thereof, concurrent with, or immediately afterdiagnosis.

The skilled artisan will appreciate that any suitable gene therapyvector containing polypeptide insulin secretagogues, DNA or DNA offragment, derivative or variant of polypeptide insulin secretagogues maybe used in accordance with this embodiment. The techniques forconstructing such a vector are known. See, e.g., Anderson, W. F., “HumanGene Therapy,” Nature, 392 25-30 (1998); Verma, I. M., and Somia, N.,“Gene Therapy—Promises, Problems, and Prospects,” Nature, 389 239-242(1998). Introduction of the polypeptide insulin secretagoguesDNA-containing vector to the target site may be accomplished using knowntechniques.

The vector includes one or more promoters. Suitable promoters which maybe employed include, but are not limited to, the retroviral LTR; theSV40 promoter; and the human cytomegalovirus (CMV) promoter described inMiller, et al., Biotechniques, 7(9): 980-990 (1989), or any otherpromoter (e.g., cellular promoters such as eukaryotic cellular promotersincluding, but not limited to, the histone, pol III, and β-actinpromoters). Other viral promoters which may be employed include, but arenot limited to, adenovirus promoters, thymidine kinase (TK) promoters,and B19 parvovirus promoters. The selection of a suitable promoter willbe apparent to those skilled in the art from the teachings containedherein.

The nucleic acid sequence encoding the polypeptide of the presentinvention is under the control of a suitable promoter. Suitablepromoters which may be employed include, but are not limited to,adenoviral promoters, such as the adenoviral major late promoter; orhetorologous promoters, such as the cytomegalovirus (CMV) promoter; therespiratory syncytial virus (RSV) promoter; inducible promoters, such asthe MMT promoter, the metallothionein promoter; heat shock promoters;the albumin promoter; the ApoAI promoter; human globin promoters; viralthymidinekinase promoters, such as the Herpes Simplex thymidine kinasepromoter; retroviral LTRs (including the modified retroviral LTRshereinabove described); the β-actin promoter; and human growth hormonepromoters. The promoter also may be the native promoter which controlsthe gene encoding the polypeptide.

The retroviral plasmid vector is employed to transduce packaging celllines to form producer cell lines. Examples of packaging cells whichmaybe transfected include, but are not limited to, the PE501, PA317,ψ-2, ψ-AM, PA12, T19-14X, VT-19-17-H2, ψCRE, ψCRIP, GP+E-86,GP+envAm12,and DAN cell lines as described in Miller, Human Gene Therapy, 1: 5-14(1990), which is incorporated herein by reference in its entirety. Thevector may transduce the packaging cells through any means known in theart. Such means include, but are not limited to, electroporation, theuse of liposomes, and CaPO₄ precipitation. In one alternative, theretroviral plasmid vector may be encapsulated into a liposome, orcoupled to a lipid, and then administered to a host. The producer cellline generates infectious retroviral vector particles which include thenucleic acid sequence(s) encoding the polypeptides. Such retroviralvector particles then may be employed, to transduce eukaryotic cells,either in vitro or in vivo. The transduced eukaryotic cells will expressthe nucleic acid sequence(s) encoding the polypeptide. Eukaryotic cellswhich may be transduced include, but are not limited to, embryonic stemcells, embryonic carcinoma cells, as well as hematopoietic stem cells,hepatocytes, fibroblasts, myoblasts, keratinocytes, endothelial cells,and bronchial epithelial cells.

A different approach to gene therapy is “transkaryotic therapy” whereinthe patient's cells are treated ex vivo to induce the dormantchromosomal genes to produce the protein of interest afterreintroduction to the patient. Transkaryotic therapy assumes theindividual has a normal complement of genes necessary for activation.Transkaryotic therapy involves introducing a promoter or other exogenousregulatory sequence capable of activating the nascent genes, into thechromosomal DNA of the patients' cells ex vivo, culturing and selectingfor active protein-producing cells, and then reintroducing the activatedcells into the patient with the intent that they then become fullyestablished. The “gene activated” cells then manufacture the protein ofinterest for some significant amount of time, perhaps for as long as thelife of the patient. U.S. Pat. Nos. 5,641,670 and 5,733,761 disclose indetail this concept, and are hereby incorporated by reference in theirentirety.

In order that this invention may be better understood, the followingexamples are set forth. These examples are for the purpose ofillustration only, and are not to be construed as limiting the scope ofthe invention in any manner. All publications mentioned herein areincorporated by reference in their entirety.

EXAMPLE 1 Protocol for Rat Islet Isolation

Sprague Dawley rats (275-320 g) were used as the source of donor islets.Briefly, the pancreas was filled with 10 ml of cold reconstitutedLiberase RI (Boehringer Manheim), harvested and incubated withadditional 5 ml enzyme solution in water bath for 30 minutes. Tissuesuspension was washed twice with cold 10% FBS/Hanks buffer (Gibco),resuspended in 8 ml 25% ficoll (Sigma) and then layered with 5 ml eachof 23%, 20% and 11% ficoll. The islets in the 20% layer aftercentrifugation were removed, washed twice with cold 10% FBS/Hank bufferand resuspended in 10% FBS/RPMI 1640 media (Sigma).

EXAMPLE 2 Protocol for Assaying Peptide-Induced Elevation of InsulinLevels in Rats

Wistar rats are fasted overnight (17 hrs) and then anesthetized withpentobarbital (0.1 ml/100 g BW). Glucose (0.4 g/kg dissolved in 1% humanalbumin-saline)+/− peptide (dissolved in 1% human albumin-saline) isinjected intravenously into the tail vein. The rats are eye-bled 1minute after the injection and 50-100 ul of the plasma are assayed forinsulin level with the Linco RIA kit (Linco Research, Inc., St. Charles,Mo.).

EXAMPLE 3 Protocol for Determining the Effect of Peptides onIntraperitoneal Glucose Tolerance in Rats

Wistar rats are fasted overnight and then anesthetized withpentobarbital. The rats were eye-bled (zero time) and the peptide (in 1%human albumin) was injected into the tail vein. Five minutes later, 1g/kg of glucose (in saline) was injected intraperitoneally, and the ratswere eye-bled after 15, 30 and 60 minutes. Plasma glucose levels weredetermined using the Technicon Axon autoanalyzer, Bayer Diagnosicsdivision of Bayer Corporation, Tarrytown N.Y., operated using Method No.SM4-2143F90 “Glucose”.

EXAMPLE 4 Protocol for Determining the Effect of Peotides on IntestinalWater Retention in Rats

Male rats were fasted for 24 hours, and their water bottles were takenaway for 2-3 hours before the start of the experiment. Peptide or salinewas injected subcutaneously into conscious rats. The rats wereeuthanized with CO₂ 10 minutes after dosing, and the small intestinedissected out and weighed (1). The intestine was cut open, the water inthe lumen absorbed with filter paper, and the intestine re-weighed (2).The amount of intestinal water (g)=weight (1)−weight (2).

EXAMPLE 5 Peptide Synthesis Methodology

The following general procedure was followed to synthesize some of thepolypeptides of the invention. Peptide synthesis was carried out by theFMOC/t-Butyl strategy (Peptide Synthesis Protocols (1994), Volume 35 byMichael W. Pennington & Ben M. Dunn) under continuous flow conditionsusing Rapp-Polymere PEG-Polystyrene resins (Rapp-Polymere, Tubingen,Germany). At the completion of synthesis, peptides are cleaved from theresin and de-protected using TFA/DTT/H₂O/Triisopropyl silane (88/5/5/2).Peptides were precipitated from the cleavage cocktail using cold diethylether. The precipitate was washed three times with the cold ether andthen dissolved in 5% acetic acid prior to lyophilization. Peptides werechecked by reversed phase chromatography on a YMC-Pack ODS-AQ column(YMC, Inc., Wilmington, N.C.) on a Waters ALLIANCE® system (WatersCorporation, Milford, Mass.) using water/acetonitrile with 3% TFA as agradient from 0% to 100% acetonitrile, and by MALDI mass spectrometry ona VOYAGER DE™ MALDI Mass Spectrometer, (model 5-2386-00, PerSeptiveBioSystems, Framingham, Mass.). Matrix buffer (50/50 dH2O/acetonitrilewith 3% TFA) peptide sample added to Matrix buffer 1/1. Those peptidesnot meeting the purity criteria of >95% are purified by reversed phasechromatography on a Waters Delta Prep 4000 HPLC system (WatersCorporation, Milford, Mass.).

EXAMPLE 6 Peptide Cloning

The recombinant expression of VIP has been attempted previously withmixed results. Simoncsits et al (Eur. J. Biochem. 178: 343-350, (1988))expressed Leu¹⁷, Gly²⁹-VIP or Leu¹⁷Gly²⁹Lys³⁰Arg³¹-VIP as a C-terminalfusion to the N-terminal part of the E. coli β-galactosidase gene in E.coli. The removal of the methionine at position 17 eliminates a CNBRcleavage site. C-terminal addition of Gly or Gly-Lys-Arg was designedfor potential in vivo C-terminal amidation by mammalian PAMase. UponCNBR cleavage of the fusion proteins at the methionine introducedN-terminal to the VIP mutants, free VIP mutants were purified and shownto possess similar activities as the native VIP, although the activitieswere measured only at saturating concentrations of the peptides.Raingeaud et al (Biochimie 78: 14-25 (1996)) expressed VIP as polymericC-terminal fusions to glutathione S-transferase (GST) in E. coli. Thefree polymeric or monomeric VIP peptides were released upon sequentialcleavages by Factor Xa and hydroxylamine. The requirement for thetwo-step cleavage led to inefficiency and a mixture of products.Polymeric or monomeric VIP peptides produced by this method were lessactive than the native VIP. An improved version of the construct usingonly Factor Xa cleavage yielded a VIP mutant with a seven residueC-terminal extension that was also less active than the native VIP(Ottavi et al, Biochimie 80: 289-293 (1998)). No expression of PACAP hasbeen reported to date. To establish a robust method for expressingPACAP, VIP, and their mutants, their genetic codes were clonedC-terminal to GST with a single Factor Xa recognition site separatingthe monomeric peptide and GST. The gene encoding Factor Xa recognitionsite fused to DNA sequence of the peptide to be produced has beensynthesized by hybridizing two overlapping single-stranded DNA fragments(70-90mers) containing a Bam HI or Xho I restriction enzyme siteimmediately 5′ to the DNA sequence of the gene to be cloned, followed byDNA synthesis of the opposite strands via the large fragment of DNApolymerase I (Life Technologies, Inc., Gaithersburg, Md.). The DNAsequence chosen for each gene was based on the reverse translation ofthe designed amino acid sequence of each peptide. In some cases, thegene encoding the peptide is generated by PCR mutagenesis (Picard, V, etal., Nucleic Acids Res 22: 2587-91 (1994); Sambrook, J., Fritsch, E. F.,& Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed.,Cold Spring Harbor Laboratory Press, New York) of a gene already made bythe method described above. The double-stranded product is then digestedby Bam HI and Xho I and ligated into pGEX-6P-1 (Amersham PharmaciaBiotech) which has also been cleaved by Bam HI and Xho I. The DNAsequences of the cloned peptide genes are listed in FIG. 8.

For example, when DNA sequences of SEQ ID NOs: 54, 55, and 56 are clonedinto pGEX-6P-1, the following polypeptide sequences were expressed asfusions with glutathione S-transferase (GST):

PACAP38: IEGRHSDGIFTDSYSRYRKQMAVKKYLAAVLGKRY (SEQ ID NO:2) KQRVKNK VIP:IEGRHSDAVFTDNYTRLRKQMAVKKYLNSILN (SEQ ID NO:1) R3P3:IEGRHSDAVFTENYTKLRKQLAAKKYLNDLKKGGT (SEQ ID NO:8)A restriction map of a typical plasmid containing the GST-peptide fusionis shown as FIG. 3.

EXAMPLE 7 Peptide Recombinant Expression and Purification

BL21 cells (Stratagene) transformed with the GST-peptide fusioncontaining plasmids were grown at 37° C. until OD₆₀₀ reached 0.6 to 1.0and induced by 1 mM IPTG (Life Technologies) for 2 hours at 37° C. 2 Lof cells were spun at 7,700 g for 15 minutes, weighed, and stored at−20° C. for at least 3 hours. The frozen cell pellet was resuspended in100 mL ice-cold PBS with 250 μl of protease inhibitor cocktail (Cat No.P-8465, Sigma Chemical) per gram of cells, sonicated at 3× for 1 minutewith 15 second breaks. Cellular debris were spun down at 10,000 g for 20minutes. The supernatant was mixed with 2 mL of 50% GlutathioneSepharose 4B resin (Pharmacia) on a shaker overnight at 4° C. The resinswere spun down at 1,500 g for 15 minutes, packed into empty Poly-PrepChromatography Columns (Bio-Rad), washed with 30 mL PBS followed by 10mL of Factor Xa buffer (1 mM CaCl₂, 100 mM NaCl, and 50 mM Tris-HCl, pH8.0). The peptides were cleaved off the column by 60 units of Factor Xa(Pharmacia) in 1 mL of Factor Xa buffer for overnight at 4° C. and runon C18 HPLC (Beckman System Gold), using a 2 mL loop and flow rate of 2mL/min with the following program: 10 minutes of Buffer A (0.1%TFA/H₂0), 30 minutes of gradient to Buffer B (0.1% TFA/ACN), 10 minutesof Buffer A, 10 minutes of gradient, and 10 minutes of Buffer A. Peakfractions (1 mL each) were collected and screened by 10-20% Tricine-SDSgel electrophoresis. Fractions containing the peptides of Table 1 werepooled and dried down. Typical yields are several hundred micrograms offree peptides per liter of E. coli culture. Recombinant peptides havebeen shown to have the same activities as their synthetic versions.

The following table contains some selected polypeptides made accordingto the Peptide Synthesis protocol discussed above (example 5), orrecombinantly as described in Example 7. Peptides produced by therecombinant method are denoted with a small letter “r” in front of thepeptide designator. Peptides produced by both recombinant and syntheticmeans are noted by asterisks next to their Peptide No's. Peptides R3P0and R3P4 were reported by Bolin, et al. (Biopolymers 37: 57-66 (1995);U.S. Pat. No. 5,677,419).

TABLE 1 SEQ ID Peptide No. Sequence NO: R3P0Ac-HSDAVFTENYTKLRKQNIeAAKKYLNDLKKGGT-NH₂ 5 R3P1Ac-HSDAVFTENYTKLRKQLAAKKYLNDLKKGGT-NH₂ 6 R3P2Ac-HSDAVFTENYTKLRKQLAAKKYLNDLKKGGT 7 rR3P3*HSDAVFTENYTKLRKQLAAKKYLNDLKKGGT 8 R3P4Ac-HSDAVFTEN(CH₃O—Y)TKLRKQNIeAAKKYLNDLKK-NH₂ 9 R3P5HSDAVFTENYTKLRKQLAAKKYLNDLKK 10 R3P8 HSDAVFTDNYTRLRKQMAVKKYLNSIKK-NH₂ 11rR3P9* HSDAVFTDNYTRLRKQMAVKKYLNSIKKGGT 12 R3P10HSDAVFTENYTKLRKQLAAKKYLNDLLNGGT 13 R3P11 HSDAVFTDNYTKLRKQLAAKKYLNDILNGGT14 R3P12* HSDAVFTDNYTRLRKQLAAKKYLNDIKKGGT 15 R3P13HSDAVFTDNYTRLRKQLAAKKYLNDIKK-NH₂ 16 R3P14HSDAVFTDNYTRLRKQMAVKKYLNDLKKGGT 17 R3P19HSDAVFTENYTKLRKQLAAKKYLNDLKKGGTSWCEPGWCR 18 R3P20HSDAVFTDNYTRLRKQMAAKKYLNDIKKGGT 19 R3P21 HSDAVFTDNYTRLRKQLAVKKYLNDIKKGGT20 R3P22 HSDAVFTDNYTRLRKQLAAKKYLNSIKKGGT 21 R3P24HSDAVFTDNYTRLRKQLAAKKYLNDIKNGGT 22 R3P25 HSDAVFTDNYTRLRKQLAVKKYLNSIKKGGT23 R3P26 HSDAVFTDNYTRLRKQMAAKKYLNSIKKGGT 24 R3P29HSDAVFTDNYTRLRKQLAVKKYLNDIKNGGT 25 R3P30 HSDAVFTDNYTRLRKQLAAKKYLNSIKNGGT26 R3P31 HSDAVFTDNYTRLRKQLAAKKYLNDIKKGG 27 R3P32HSDAVFTDNYTRLRKQLAAKKYLNDIKKG 28 rR3P33* HSDAVFTDNYTRLRKQLAAKKYLNDIKK 29R3P34 HSDAVFTDNYTRLRKQLAAKKYLNDIKKQ 30 R3P35HSDAVFTDNYTRLRKQLAAKKYLNDIKKNQ 31 R3P36 HSDAVFTDNYTRLRKQLAAKKYLNDIKKKRY32 rR3P41 HSDAVFTDNYTRLRKQMAVKKYLNSIKK 33 rR3P42HSDAVFTDNYTRLRKQMAVKKYLNSIKN 34 rR3P43 HSDAVFTDNYTRLRKQMAVKKYLNSILK 35rR3P44 HSDAVFTDNYTELRKQMAVKKYLNSILN 36 rR3P45HSDAVFTDNYTRLREQMAVKKYLNSILN 37 rR3P46 HSDAVFTDNYTRLRKQLAVKKYLNSILN 38rR3P47 HSDAVFTDNYTRLRKQMAAKKYLNSILN 39 rR3P48HSDAVFTDNYTRLRKQMAVKKYLNDILN 40 rR3P49 HSDAVFTDNYTRLRKQMAAKKYLNSIKN 41rR3P50 HSDAVFTDNYTRLRKQMAAKKYLNSILK 42 rR3P51*HSDAVFTDNYTRLRKQMAAKKYLNSIKK 43 rR3P52 HSDAVFTDNYTRLRKQMAAKKYLNSIKKKRY44 rR3P53* HSDAVFTDNYTRLRKQMAAKKYLNSIKKKR 45 rR3P54HSDAVFTDNYTRLRKQMAAKKYLNSIKKK 46 rR3P55* HSDAVFTDNYTRLRKQMAAKKYLNSIKNKRY47 rR3P56 HSDAVFTDNYTRLRKQMAVKKYLNSIKKKRY 48 rR3P57HSDAVFTDNYTRLRKQMAVKKYLNSIKKKR 49 rR3P58 HSDAVFTDNYTRLRKQMAVKKYLNSIKKK50 rR3P59 HSDAVFTDNYTRLRKQMAVKKYLNSIKNKRY 51 rR3P60HSDAVFTDNYTRLRKQVAAKKYLQSIKK 52 rR3P61 HSDAVFTDNYTRLRKQIAAKKYLQTIKK 53R3P6 HSDGIFTESYSRYRKQMAVKKYLAALKKKRYKQRVKNK 57 R3P7HSDAVFTENYTRLRKQMAVKKYLNSLKK-NH₂ 58 R3P15HSDGIFTDSYSRYRKQMAVKKYLSAVRHGQT-NH₂ 59 R3P16HSDGIFTDSYSRYRKQMAVKKYLAAVKQGGT-NH₂ 60 R3P17HSDGIFTDSYSRYRKQMAVKKYLAAVKKYLAAVRHG-NH₂ 61 R3P18SWCEPGWCRHSDAVFTENYTKLRKQLAAKKYLNDLKKGGT 62 R3P23HSDAVFTDNYTRLRKQLAAKKYLNDILKGGT 63 R3P27 HSDAVFTDNYTRLRKQLAAKKYLNDILNGGT64 R3P28 HSDAVFTDNYTRLRKQLAVKKYLNDILKGGT 65 R3P37HSDGIFTDSYSRYRKQLAAKKYLADVKKGGT 66 R3P38 HSDGIFTDSYSRYRKQLAAKKYLADVKK 67R3P39 HSDGIFTDSYSRYRKQLAVKKYLAAVKK 68 R3P40 HSDGIFTDSYSRYRKQMAVKKYLAAVKK69 R3P62 HSDAVFTDNYTRLRKQVAAKKYLNSIKK 70 R3P65HSDAVFTDNYTRLRKQMAAKKYLNSIKNKR 71 R3P66 HSDAVFTDNYTRLRKQVAAKKYLQSIKNKRY72 R3P67 HSDAVFTDNYTRLRKQLAAKKYLNTIKNKRY 73 R3P68HSDAVFTDNYTRLRKQVAAKKYLNSIKNKRY 74 R3P69 HSDAVFTDNYTRLRKQMAAKKYLQSIKNKRY75 R3P70 HSDAVFTDNYTRLRKQMAAKKYLNTIKNKRY 76 R3P71HSDAVFTDQYTRLRKQMAAKKYLNSIKNKRY 77 R3P72 HSDAVFTDQYTRLRKQLAAKKYLNTIKNKRY78 R3P73 HSDAVFTDNYTRLRKQMAAHKYLNSIKNKRY 79 R3P74HSDAVFTDNYTRLRKQMAAKHYLNSIKNKRY 80 R3P75 HSDAVFTDQYTRLRKQLAAHKYLNTIKNKRY81 R3P76 HSDAVFTDQYTRLRKQLAAKHYLNTIKNKRY 82 R3P77HSDAVFTDNYTRLRKQVAAKKYLQSIKKKR 83 R3P78 HSDAVFTDNYTRLRKQVAAKKYLNSIKKKR84 R3P79 HSDAVFTDNYTRLRKQVAAKKYLNSIKNKRY 85 R3P80HSDAVFTDNYTRLRKQVAVKKYLQSIKKKR 86 R3P81 HSDAVFTDNYTRLRKQVAVKKYLQSIKKK 87R3P82 HSDAVFTDNYTRLRKQVAVKKYLQSIKNKRY 88 R3P83HSDAVFTDNYTRLRKQVAAKKYLQSILKKRY 89 R3P84 HSDAVFTDNYTRLRKQVAAKKYLQSILKKR90 R3P85 HSDAVFTDNYTRLRKQVAAKKYLQSILKK 91 R3P86HSDAVFTDNYTRLRKQVAAKKYLQSIKNK 92 R3P87 HSDAVFTDNYTRLRKQVAVKKYLQSILKKRY93 R3P88 HSDAVFTDNYTRLRKQVAVKKYLQSILKKR 94 R3P89HSDAVFTDNYTRLRKQVAVKKYLQSILKK 95 R3P92 HSDAVFTDNYTRLRKQVAAKKYLQSILNKRY97 R3P93 HSDAVFTDNYTRLRKQVAAKKYLQSILNKR 98 R3P94HSDAVFTDNYTRLRKQVAAKKYLQSILNK 99 rR3P97 HSDAVFTDNYTRLRKQMACKKYLNSIKNKR100 rR3P98 HSDAVFTDNYTRLRKQMADKKYLNSIKNKR 101 rR3P99HSDAVFTDNYTRLRKQMAEKKYLNSIKNKR 102 rR3P100HSDAVFTDNYTRLRKQMAFKKYLNSIKNKR 103 rR3P101HSDAVFTDNYTRLRKQMAGKKYLNSIKNKR 104 rR3P102HSDAVFTDNYTRLRKQMAHKKYLNSIKNKR 105 rR3P103HSDAVFTDNYTRLRKQMAIKKYLNSIKNKR 106 rR3P104HSDAVFTDNYTRLRKQMAKKKYLNSIKNKR 107 rR3P105HSDAVFTDNYTRLRKQMALKKYLNSIKNKR 108 rR3P106HSDAVFTDNYTRLRKQMAMKKYLNSIKNKR 109 rR3P107HSDAVFTDNYTRLRKQMANKKYLNSIKNKR 110 rR3P108HSDAVFTDNYTRLRKQMAPKKYLNSIKNKR 111 rR3P109HSDAVFTDNYTRLRKQMAQKKYLNSIKNKR 112 rR3P110HSDAVFTDNYTRLRKQMARKKYLNSIKNKR 113 rR3P111HSDAVFTDNYTRLRKQMASKKYLNSIKNKR 114 rR3P112HSDAVFTDNYTRLRKQMATKKYLNSIKNKR 115 rR3P113HSDAVFTDNYTRLRKQMAVKKYLNSIKNKR 116 rR3P114HSDAVFTDNYTRLRKQMAWKKYLNSIKNKR 117 rR3P115HSDAVFTDNYTRLRKQMAYKKYLNSIKNKR 118 rR3P116HSDAVFTDNYTRLRKQMAAKKYLNSIANKR 119 rR3P117HSDAVFTDNYTRLRKQMAAKKYLNSICNKR 120 rR3P118HSDAVFTDNYTRLRKQMAAKKYLNSIDNKR 121 rR3P119HSDAVFTDNYTRLRKQMAAKKYLNSIENKR 122 rR3P120HSDAVFTDNYTRLRKQMAAKKYLNSIFNKR 123 rR3P121HSDAVFTDNYTRLRKQMAAKKYLNSIGNKR 124 rR3P122HSDAVFTDNYTRLRKQMAAKKYLNSIHNKR 125 rR3P123HSDAVFTDNYTRLRKQMAAKKYLNSIINKR 126 rR3P124HSDAVFTDNYTRLRKQMAAKKYLNSIMNKR 127 rR3P125HSDAVFTDNYTRLRKQMAAKKYLNSINNKR 128 rR3P126HSDAVFTDNYTRLRKQMAAKKYLNSIPNKR 129 rR3P127HSDAVFTDNYTRLRKQMAAKKYLNSIQNKR 130 rR3P128HSDAVFTDNYTRLRKQMAAKKYLNSIRNKR 131 rR3P129HSDAVFTDNYTRLRKQMAAKKYLNSISNKR 132 rR3P130HSDAVFTDNYTRLRKQMAAKKYLNSITNKR 133 rR3P131HSDAVFTDNYTRLRKQMAAKKYLNSIVNKR 134 rR3P132HSDAVFTDNYTRLRKQMAAKKYLNSIWNKR 135 rR3P133HSDAVFTDNYTRLRKQMAAKKYLNSIYNKR 136 rR3P134HSDAVFTDNYTRLRKQMAAKKYLNSIKNAR 137 rR3P135HSDAVFTDNYTRLRKQMAAKKYLNSIKNCR 138 rR3P136HSDAVFTDNYTRLRKQMAAKKYLNSIKNDR 139 rR3P137HSDAVFTDNYTRLRKQMAAKKYLNSIKNER 140 rR3P138HSDAVFTDNYTRLRKQMAAKKYLNSIKNFR 141 rR3P139HSDAVFTDNYTRLRKQMAAKKYLNSIKNGR 142 rR3P140HSDAVFTDNYTRLRKQMAAKKYLNSIKNHR 143 rR3P141HSDAVFTDNYTRLRKQMAAKKYLNSIKNIR 144 rR3P142HSDAVFTDNYTRLRKQMAAKKYLNSIKNLR 145 rR3P143HSDAVFTDNYTRLRKQMAAKKYLNSIKNMR 146 rR3P144HSDAVFTDNYTRLRKQMAAKKYLNSIKNNR 147 rR3P145HSDAVFTDNYTRLRKQMAAKKYLNSIKNPR 148 rR3P146HSDAVFTDNYTRLRKQMAAKKYLNSIKNQR 149 rR3P147HSDAVFTDNYTRLRKQMAAKKYLNSIKNRR 150 rR3P148HSDAVFTDNYTRLRKQMAAKKYLNSIKNSR 151 rR3P149HSDAVFTDNYTRLRKQMAAKKYLNSIKNTR 152 rR3P150HSDAVFTDNYTRLRKQMAAKKYLNSIKNVR 153 rR3P151HSDAVFTDNYTRLRKQMAAKKYLNSIKNWR 154 rR3P152HSDAVFTDNYTRLRKQMAAKKYLNSIKNYR 155 rR3P153HSDAVFTDNYTRLRKQMAAKKYLNSIKNKA 156 rR3P155HSDAVFTDNYTRLRKQMAAKKYLNSIKNKD 157 rR3P156HSDAVFTDNYTRLRKQMAAKKYLNSIKNKE 158 rR3P157HSDAVFTDNYTRLRKQMAAKKYLNSIKNKF 159 rR3P158HSDAVFTDNYTRLRKQMAAKKYLNSIKNKG 160 rR3P159HSDAVFTDNYTRLRKQMAAKKYLNSIKNKH 161 rR3P160HSDAVFTDNYTRLRKQMAAKKYLNSIKNKI 162 rR3P161HSDAVFTDNYTRLRKQMAAKKYLNSIKNKK 163 rR3P162HSDAVFTDNYTRLRKQMAAKKYLNSIKNKL 164 rR3P163HSDAVFTDNYTRLRKQMAAKKYLNSIKNKM 165 rR3P164HSDAVFTDNYTRLRKQMAAKKYLNSIKNKN 166 rR3P165HSDAVFTDNYTRLRKQMAAKKYLNSIKNKP 167 rR3P166HSDAVFTDNYTRLRKQMAAKKYLNSIKNKQ 168 rR3P167HSDAVFTDNYTRLRKQMAAKKYLNSIKNKS 169 rR3P168HSDAVFTDNYTRLRKQMAAKKYLNSIKNKT 170 rR3P169HSDAVFTDNYTRLRKQMAAKKYLNSIKNKV 171 rR3P170HSDAVFTDNYTRLRKQMAAKKYLNSIKNKW 172 rR3P171HSDAVFTDNYTRLRKQMAAKKYLNSIKNKY 173 R3P172HSDAVFTDNYTRLRKQVAAKKYLQSIKNKRYSWCEPGWCR 174 R3P173HSDAVFTDDYTRLRKEVAAKKYLESIKDKRY 175 PAC1 ESDGIFTDSYSRYRKQMAVKKYLAAVL-NH₂176 PAC2 HKDGIFTDSYSRYRKQMAVKKYLAAVL-NH₂ 177 PAC3HSKGIFTDSYSRYRKQMAVKKYLAAVL-NH₂ 178 PAC4 HSDKIFTDSYSRYRKQMAVKKYLAAVL-NH₂179 PAC5 HSDGKFTDSYSRYRKQMAVKKYLAAVL-NH₂ 180 PAC6HSDGIKTDSYSRYRKQMAVKKYLAAVL-NH₂ 181 PAC7 HSDGIFKDSYSRYRKQMAVKKYLAAVL-NH₂182 PAC8 HSDGIFTKSYSRYRKQMAVKKYLAAVL-NH₂ 183 PAC9HSDGIFTDKYSRYRKQMAVKKYLAAVL-NH₂ 184 PAC10HSDGIFTDSKSRYRKQMAVKKYLAAVL-NH₂ 185 PAC11HSDGIFTDSYKRYRKQMAVKKYLAAVL-NH₂ 186 PAC12HSDGIFTDSYSEYRKQMAVKKYLAAVL-NH₂ 187 PAC13HSDGIFTDSYSRKRKQMAVKKYLAAVL-NH₂ 188 PAC14HSDGIFTDSYSRYEKQMAVKKYLAAVL-NH₂ 189 PAC15HSDGIFTDSYSRYREQMAVKKYLAAVL-NH₂ 190 PAC16HSDGIFTDSYSRYRKKMAVKKYLAAVL-NH₂ 191 PAC17HSDGIFTDSYSRYRKQKAVKKYLAAVL-NH₂ 192 PAC18HSDGIFTDSYSRYRKQMKVKKYLAAVL-NH₂ 193 PAC19HSDGIFTDSYSRYRKQMAKKKYLAAVL-NH₂ 194 PAC20HSDGIFTDSYSRYRKQMAVEKYLAAVL-NH₂ 195 PAC21HSDGIFTDSYSRYRKQMAVKEYLAAVL-NH₂ 196 PAC22HSDGIFTDSYSRYRKQMAVKKKLAAVL-NH₂ 197 PAC23HSDGIFTDSYSRYRKQMAVKKYKAAVL-NH₂ 198 PAC24HSDGIFTDSYSRYRKQMAVKKYLKAVL-NH₂ 199 PAC25HSDGIFTDSYSRYRKQMAVKKYLAKVL-NH₂ 200 PAC26HSDGIFTDSYSRYRKQMAVKKYLAAKL-NH₂ 201 PAC27HSDGIFTDSYSRYRKQMAVKKYLAAVK-NH₂ 202 rR3P174HSDAVFTDNYTRLRKQMAAKKYLNSIKNRI 322 rR3P175HSDAVFTDNYTRLRKQMAGKKYLNSIKNRI 323 rR3P176HSDAVFTDNYTRLRKQMAKKKYLNSIKNRI 324 rR3P177HSDAVFTDNYTRLRKQMARKKYLNSIKNRI 325 rR3P178HSDAVFTDNYTRLRKQMASKKYLNSIKNRI 326 rR3P179HSDAVFTDNYTRLRKQMAAKKYLNSIPNRI 327 rR3P180HSDAVFTDNYTRLRKQMAGKKYLNSIPNRI 328 rR3P181HSDAVFTDNYTRLRKQMAKKKYLNSIPNRI 329 rR3P182HSDAVFTDNYTRLRKQMARKKYLNSIPNRI 330 rR3P183HSDAVFTDNYTRLRKQMASKKYLNSIPNRI 331 rR3P184HSDAVFTDNYTRLRKQMAAKKYLNSIQNRI 332 rR3P185HSDAVFTDNYTRLRKQMAGKKYLNSIQNRI 333 rR3P186HSDAVFTDNYTRLRKQMAKKKYLNSIQNRI 334 rR3P187HSDAVFTDNYTRLRKQMARKKYLNSIQNRI 335 rR3P188HSDAVFTDNYTRLRKQMASKKYLNSIQNRI 336 rR3P189HSDAVFTDNYTRLRKQMAAKKYLNSIRNRI 337 rR3P190HSDAVFTDNYTRLRKQMAGKKYLNSIRNRI 338 rR3P191HSDAVFTDNYTRLRKQMAKKKYLNSIRNRI 339 rR3P192HSDAVFTDNYTRLRKQMARKKYLNSIRNRI 340 rR3P193HSDAVFTDNYTRLRKQMASKKYLNSIRNRI 341

EXAMPLE 8 Insulin Secretion by Rat Islets

Peptide R3P3 (0.1-100 nM) stimulates insulin secretion from isolated ratislets in a glucose-dependent fashion. These studies compare the effectson islet cells of R3P3 peptide and GLP-1.

Rat islets were isolated and treated with GLP-1 or R3P3 at either 3 or 8mM glucose in the medium in accordance with the rat islet protocoldescribed above in example 1. As shown by FIGS. 4A-4B, peptide R3P3significantly enhances the release of insulin from islets in aconcentration-dependent fashion and this effect is similar to that ofGLP-1, a known insulin secretagogue.

EXAMPLE 9 In Vivo Insulin and Glucose Response

As shown in Tables 2 and 3 below, polypeptides that activate the R3receptor also potentiate glucose-induced increase in plasma insulinlevels when compared to glucose alone. This increase in insulin causesconcomitant decrease in plasma glucose.

In accordance with the protocol of example 2 above, overnight fastedWistar rats were anesthetized with pentobarital; i.v. injected withglucose± peptide and eye bled after 1 minute. N=12 rats/group. The graphin FIG. 5 shows that the polypeptide R3P3 causes an increase in glucosedisposal that accompanies the increase in insulin secretion. The peptideor vehicle was given i.v. followed by a glucose load given i.p. inaccordance with example 3. The plasma glucose was followed over the timeperiod indicated. As shown in the graph, R3P3 markedly accelerated thedisposal of blood glucose.

EXAMPLE 10 Diarrhea Side Effects

As described in the protocol of example 4 above, fasted rats wereinjected s.c. with the indicated peptide (5 nmol/kg or 22-24 nmol/kg).Five minutes after the injection, 0.3 ml of water was given p.o. Fivemin after the water dose, the animals were euthanized and the watercontent in the small intestine determined. As shown in FIG. 6, VIPinjections at the two doses caused a marked increase in the watercontent of the small intestine lumen over the vehicle (saline) control.At the highest dose, the R3 peptides caused only a very small increase(i.e., roughly 10%) in comparison to VIP. At the 5 nmol/kg dose, thepeptides did not produce any change in water content in the small gut.The degree of water retention was used as an index of R2 activation invivo.

EXAMPLE 11 Effect of Peptides on Intraperitoneal Glucose Tolerance inRats

Wistar rats were fasted overnight and then anesthetized withPentobarbital. The rats were eye-bled (zero time) and the peptide (in 1%human albumin) was injected subcutaneously. Five minutes later, 1 g/kgof glucose (in saline) was injected intraperitoneally, and the rats wereeye-bled after 30 minutes. Plasma glucose levels were determined usingthe Axon autoanalyzer, and are shown in FIG. 7.

FIG. 7 shows that plasma glucose elevated to 160 mg/dl above basal (100mg/dl) in rats treated with vehicle 30 minutes after IPGTT (IP GlucoseTolerance Test). In rats injected with peptides R3P3, R3P12 and R3P13,this elevation of plasma glucose was significantly reduced, verifyingthe insulin-producing effect. At 1 nmole/kg s.c., the glucose-loweringeffect of each peptide was similar to that observed with an equivalentdose of GLP-1.

EXAMPLE 12 Glucose-dependent Insulin Secreting Polypeptides

Table 2 contains a list of the peptides that stimulated release ofinsulin in vivo in the IPGTT assay, or in vitro through the rat isletassay. As shown by the data, the peptides enhance glucose-mediatedinsulin release in vivo and in vitro.

Plasma insulin: Data are expressed as % of plasma insulin one minuteafter IVGTT (0.4 g/kg glucose) with either saline, 0.1 nmol/kg P51, P55,P60, P66 or 1 nmole/kg of the other peptides in Wistar rats. Blood wasdrawn from the eye and insulin was measured with the rat insulin RIA kit(Linco Research, Inc., St. Charles, Mo.).

Plasma glucose: Data are expressed as % of vehicle of plasma glucosearea under the curve after IPGTT (1 g/kg glucose) after treatment with 1nmol/kg dose of the peptide. PACAP27 has been reported to induce insulinsecretion but does not affect plasma glucose levels (Filipsson , K. etal., J. Clin. Endocrin. & Metabolism 82: 3093-3098 (1997)). The presentinventors have shown for the first time that this is because the effectsof R2 and R3 on glucose tend to cancel each other out. The R2-selectiveagonist [K15, R16, L27]VIP(1-7)/GRF(8-27) (Gourlet, P. et al., Peptides18:1539-45 (1997)), defined as R2P1, increases plasma glucose level by14% while R3-selective agonists lower plasma glucose level by ˜20%.Therefore, R3-selectivity appears to be a desirable attribute formedicaments which are to be employed in achieving blood glucosereduction, for treatment of type 2 diabetes.

Islet insulin release: Rat islets were isolated from Sprague-Dawley ratsas described in example 1 and treated with either vehicle or specifiedpeptide (10 nM) for 2 hrs. Insulin concentration in the medium wasmeasured with the Linco rat insulin RIA kit. Glucose concentration inthe medium was 8 mM. The data are expressed as % of [insulin] in 8 mMglucose alone. No polypeptide-induced increases in insulin concentrationwere observed at 3 mM glucose; thus, the insulin releasing activity ofthese polypeptides are glucose-dependent.

TABLE 2 Plasma Glucose Plasma Insulin (% of Basal) Islet Insulin ReleasePeptide (% of Basal) i.v. s.c. (% of Basal) PACAP 27 320 186 R2P1 216114 R3P0 77 264 R3P1 480 73 250 R3P3 361 77 72 275 R3P9 221 R3P10 174R3P12 302 76 324 R3P13 465 77 170 R3P19 285 R3P36 255 73 78 P51 259 P55208 P60 283 R3P66 388 82 184 R3P77 388 R3P80 360 R3P81 302

EXAMPLE 13 Pharmaceutical Composition—IV Formulation

A sterile injectable formulation is made from 4 mg of a polypeptide ofSEQ ID NO: 72 and 1 liter of sterile saline, using a manufacturingprocess well known in the art.

EXAMPLE 14 Pharmaceutical Composition—IV Formulation

A sterile injectable formulation is made from 400 mg of a polypeptide ofSEQ ID NO 174 and 1 liter of sterile saline, using a manufacturingprocess well known in the art.

EXAMPLE 15 Effect of PACAP27, VIP and PACAP Receptor-selective PeptideAgonists on Heart Rate in Conscious Dogs

Protocol:

Beagle dogs were put into a sling where they have been trained to standfor up to 3 hours. The cuff of the heart rate monitor was placed aroundthe tail of the dog.

Saline was injected into the cephalic vein and heart rate monitoredevery 2 minutes to establish a baseline. After 10 minutes, peptide wasinjected and heart rate monitored every 2 minutes for the next 20minutes. If heart rate was normal at that time, a higher dose was givenand heart rate monitored for 20 minutes. The area under the curve (AUC)for the first 10 minutes of heart rate change induced by the polypeptidewas plotted as % over vehicle AUC against polypeptide concentration.PACAP27 and the R1-selective agonist maxadilan (Moro, O., J. Biol. Chem.272:966-970 (1997)) possess similar potency in heart rate increase. VIPwhich activates both R2 and R3 but not R1, R2-selective agonist R2P1,and R3 selective agonists R3P0, R3P3, R3P19, R3P36, R3P51, and R3P53 areat least 10-fold less potent than PACAP27 or maxidilan. Thus, thecardiovascular effect of PACAP27 can be mostly attributed to PACAP-R1activation. All peptides are full agonists at their respective receptorswith comparable affinities. R3P0 is the Roche analog RO 25-1553 that hasbeen shown to display selectivity for PACAP-R3 of at least 100-fold overR1 and R2 (Gourlet et al, Peptides 18:4030408 (1997)).

EXAMPLE 16 Cyclic AMP SPA

CHO cells expressing the PACAP R3 were plated in 96-well plates (Costar)at 8×10⁴ cell/well and grown at 37C for 24 hours in αMEM+nucleosides+glutamine (Giobco BRL), 10% FBS, 100 μg/ml Pen/Strep,0.3 mg/ml glutamine, 1 mM HEPES, 0.5 mg/ml Geneticin (Gibco BRL). Themedia was removed and the plates were washed with PBS. The cells wereincubated with a peptide, in Hepes-PBS-BSA with 0.4 mg/mlSoybean TrypsinInhibitor, 0.5 mg/ml Bacitracin, 100 uM IBMX, for 15 min at 37 C. CyclicAMP in the cell extracts was quantitated using the cAMP SPA directscreening assay system (Amersham Pharmacia Biotech Inc, Piscataway,N.J.). The peptides shown in Table 3 were assayed for cAMP activity.

Table 3 reports In vitro cAMP SPA results on CHO cells transfected withPACAP-R2 or PACAP-R3. EC50 is defined as the concentration of thepolypeptide at which 50% of maximum PACAP27 activity is achieved. “NA”denotes no detectable activities. “R3 Selectivity” is derived from theratio of EC50 at R2 versus EC50 at R3. Most of the followingpolypeptides are designed based on VIP, which has been shown to lackactivity at R1 (Vaudry D. et al., 2000, Pharmacological Reviews, 52:269-324). Therefore, it is believed that these polypeptides do notpossess appreciable activity at R1. Peptides designed based on VIPinclude SEQ ID NO: 6-53, 62-65, and 70-175.

TABLE 3 Seq ID Peptide NO R2 EC50, nM R3 EC50, nM R3 Selectivity VIP 10.1 0.08 1.3 R3P0 5 >100 0.4 >250 R3P1 6 >100 2 >50 R3P2 7 >1000 3 >300R3P3 8 100 0.75 130 R3P5 10 200 7 30 R3P8 11 2 1.4 1.5 R3P9 12 40 2 20R3P10 13 3 11 0.3 R3P11 14 10 3 3 R3P12 15 >100 0.5 >200 R3P13 16 163 533 R3P14 17 50 17 3 R3P19 18 42 1.4 30 R3P20 19 330 1.4 230 R3P21 20 170.3 60 R3P22 21 38 1.6 24 R3P24 22 45 1.3 34 R3P25 23 15 0.7 20 R3P2624 >100 0.55 >180 R3P29 25 >100 0.5 >200 R3P30 26 20 0.4 50 R3P3127 >100 0.3 >300 R3P32 28 84 0.4 200 R3P33 29 >100 0.5 >200 R3P3430 >100 1.4 >70 R3P35 31 >100 2.6 >40 R3P36 32 >90 0.4 >200 R3P41 33 80.08 100 R3P42 34 0.3 0.03 10 R3P43 35 0.8 0.08 10 R3P44 36 8 1.3 6R3P45 37 NA NA R3P46 38 0.4 0.06 7 R3P47 39 0.7 0.12 6 R3P48 40 1 0.13 8R3P49 41 8 0.27 30 R3P50 42 0.7 0.13 6 R3P51 43 23 0.26 90 R3P52 44 >1000.4 >250 R3P53 45 500 0.2 2500 R3P54 46 >100 0.5 >200 R3P55 47 50 0.17280 R3P56 48 40 0.4 100 R3P57 49 42 0.23 190 R3P58 50 55 0.32 170 R3P5951 10 0.15 70 R3P60 52 120 1 120 R3P61 53 110 0.8 140 R3P6 57 220 80 3R3P7 58 2 4 0.5 R3P15 59 12 5 2 R3P16 60 14 10 1.4 R3P17 61 9 4 2 R3P1862 NA NA R3P23 63 10 0.43 23 R3P27 64 6.4 0.8 8 R3P28 65 8 7 1 R3P37 6671 4 18 R3P38 67 17 2.3 7 R3P39 68 1 0.5 2 R3P40 69 1.4 0.7 2 R3P62 70180 1.8 100 R3P65 71 80 0.6 130 R3P66 72 100 0.4 250 R3P67 73 100 0.3330 R3P68 74 130 0.5 260 R3P69 75 90 0.5 190 R3P70 76 >100 0.4 >250R3P71 77 56 0.09 660 R3P72 78 >100 0.16 >600 R3P73 79 50 0.3 170 R3P7480 90 0.6 150 R3P75 81 >150 0.3 >500 R3P76 82 >150 0.1 >1500 R3P77 83200 0.4 500 R3P78 84 250 1.1 230 R3P79 85 100 0.5 200 R3P80 86 88 0.44200 R3P81 87 50 0.5 100 R3P82 88 10 0.4 23 R3P83 89 5 0.08 60 R3P84 902.5 0.06 40 R3P85 91 5 0.18 30 R3P86 92 90 0.8 110 R3P87 93 0.6 0.2 3R3P88 94 0.9 0.08 12 R3P89 95 0.9 0.06 15 R3P92 98 2 0.02 100 R3P93 98 60.14 40 R3P94 99 9 0.09 100 R3P98 101 NA NA R3P99 102 40 1.0 40 R3P100103 10 0.3 30 R3P101 104 400 1.0 400 R3P102 105 300 60.0 5 R3P103 1060.4 0.05 8 R3P104 107 100 0.2 500 R3P105 108 1 0.3 3 R3P106 109 2 0.1 20R3P107 110 1000 200.0 5 R3P108 111 1000 300.0 3 R3P109 112 1000 10.0 100R3P110 113 100 0.5 200 R3P111 114 1000 3.0 300 R3P112 115 4 0.1 40R3P113 116 3 0.3 10 R3P114 117 20 2.0 10 R3P115 118 300 6.0 50 R3P116119 20 1.0 20 R3P118 121 15 0.5 30 R3P119 122 15 0.5 30 R3P120 123 100.2 50 R3P121 124 50 1.0 50 R3P122 125 10 0.2 50 R3P123 126 5 0.1 50R3P124 127 3 0.2 15 R3P125 128 60 2.0 30 R3P126 129 200 1.0 200 R3P127130 300 0.5 600 R3P128 131 60 0.3 200 R3P129 132 50 1.0 50 R3P130 133 401.0 40 R3P131 134 20 0.3 70 R3P132 135 10 0.2 50 R3P133 136 8 0.1 80R3P134 137 40 0.4 100 R3P136 139 20 0.3 70 R3P137 140 30 0.3 100 R3P139142 20 0.4 50 R3P140 143 15 0.3 50 R3P141 144 20 0.2 100 R3P142 145 60.2 30 R3P143 146 6 0.2 30 R3P144 147 300 3.0 100 R3P145 148 50 0.5 100R3P146 149 30 0.3 100 R3P147 150 100 0.2 500 R3P148 151 30 0.3 100R3P149 152 40 0.5 80 R3P150 153 40 0.8 50 R3P153 156 40 0.2 200 R3P155157 40 0.4 100 R3P156 158 100 1.0 100 R3P157 159 50 0.3 170 R3P158 160 60.07 90 R3P159 161 200 0.5 400 R3P160 162 100 0.2 500 R3P161 163 60 0.2300 R3P162 164 20 0.1 200 R3P163 165 40 0.2 200 R3P164 166 100 0.3 300R3P165 167 150 0.5 300 R3P166 168 50 0.1 500 R3P167 169 300 1.0 300R3P168 170 60 0.2 300 R3P169 171 60 0.2 300 R3P170 172 20 0.1 200 R3P171173 80 0.4 200 R3P172 174 77 2.6 29 R3P173 175 NA 200 PAC1 176 970 10 97PAC2 177 NA 34 PAC3 178 NA NA PAC4 179 45 7 6 PAC5 180 1.8 0.7 2 PAC6181 NA NA PAC7 182 NA NA PAC8 183 43 47 1 PAC9 184 0.9 0.7 1 PAC10 185110 27 4 PAC11 186 10 140 0.1 PAC12 187 150 3 50 PAC13 188 3 0.5 6 PAC14189 110 1.6 70 PAC15 190 2.4 0.2 12 PAC16 191 0.2 0.2 1 PAC17 192 0.250.15 1.6 PAC18 193 0.7 1.1 0.7 PAC19 194 8 0.4 20 PAC20 195 20 0.7 30PAC21 196 2.5 0.24 10 PAC22 197 2 15 0.1 PAC23 198 170 13 13 PAC24 1990.3 0.2 1.5 PAC25 200 0.13 0.04 3 PAC26 201 0.25 0.3 1 PAC27 202 1.5 1.11.4 rR3P174 322 18 0.20 90 rR3P175 323 400 2.2 180 rR3P176 324 300 2.0150 rR3P177 325 110 1.6 70 rR3P178 326 80 0.75 110 rR3P179 327 230 1.5150 rR3P180 328 >100 6.7 >20 rR3P181 329 280 5.1 50 rR3P182 330 280 3.290 rR3P183 331 >150 5.4 >30 rR3P184 332 10 0.37 30 rR3P185 333 180 4.540 rR3P186 334 70 1.6 44 rR3P187 335 >130 1.6 >80 rR3P188 336 150 2.2 70rR3P189 337 1.3 0.04 30 rR3P190 338 220 2.2 100 rR3P191 339 >200 2.7 >80rR3P192 340 40 0.60 60 rR3P193 341 200 1.9 110

EXAMPLE 17 Polyclonal Antibody Production

Synthesis of the peptide Ac-CRKQVMKKYLQSIKNKRY COOH was performed on anApplied Biosystems 430A peptide synthesizer using fmoc chemistry withHBTU activation of amino acids. The peptide was cleaved using a 84.6%TFA, 4.4% phenol, 4.4% water, 4.4% thioanusol, and 2.2% ethandithiolcocktail. The crude peptide was purified using a C18 reverse phasecolumn with a 0.1% TFA/CH3CN gradient. Evaluation of purity wasperformed on a PerSeptive V Biosystems Voyager DE Pro MALDI massspectrometer. The cysteine residue was coupled to KLH using the Piercelmject Maleimide Activated mcKLH kit and protocol (Pierce , Rockford,Ill.). Rabbits were immunized using the following polyclonal antiserumimmunization schedule:

-   Day 0-10 ml prebleed for baseline serum    -   250 ug each peptide in 1 ml emulsion of Complete Freunds        Adjuvant,    -   0.1 ml/site×10 sites subcutaneously-   Day 14—Boost 250 μg each peptide in 1 ml emulsion of Incomplete    Freunds Adjuvant    -   0.1 ml/site×10 sites subcutaneously-   Day 21-35 ml bleed-   Day 35—Boost 250 μg each peptide in 1 ml emulsion of Incomplete    Freunds Adjuvant    -   0.1 ml/site×10 sites subcutaneously-   Day 42-35 ml bleed-   Day 56—Boost 250 μg each peptide in 1 ml emulsion of Incomplete    Freunds Adjuvant    -   0.1 ml/site×10 sites subcutaneously-   Day 63-35 ml bleed-   Day 77—Boost 250 μg each peptide in 1 ml emulsion of Incomplete    Freunds Adjuvant    -   0.1 ml/site×10 sites subcutaneously-   Day 84—Terminal bleed    Antibodies were Characterized Using the Following Protocol:

Immulon III plate (DYNATECH LABORATORIES, INC, Chantilly, Va.) wascoated with P66 peptide (0.3-100 ng range) in 100 ul of EIA coatingbuffer 1.6 L of 0.1M NaHCO3+0.4 L of 0.1M Na2CO3 pH9.5) for 3 hours atroom temperature (RT). The plate was blotted with 100 ul of 5% milk TBSTween 20 (10 mM tris pH8.0, 150 mM NaCl, 0.05% Tween-20 (SIGMA P-1379))for 1 hour at RT and washed 3 times with TBS Tween. R3P66 antibody wasadded to the well in 100 ul of 5% bloto (TBS-Tween 20+5% milk ) for 2hours RT followed by a wash with TBS Tween (repeat wash 5 times).Secondary antibody (BioRad goat anti rabbit Alkaline Phosphataseconjugate) was added to the well at 1:1000 dilution in 100 ul of 5%bloto for 1 hour. The plate was washed 5 times with TBS Tween.p-Nitrophenyl Phosphate (SIGMA 104-105) 0.5 mg/ml of substrate buffer(1M Diethanolamine, 0.5 uM MgCl2*6H2O, pH 9.8 w/HCl) in 100 ul andincubated at RT for 1 hour to O/N. The plate was read at OD 405 inSPECTRAmax 250 (Molecular Devices Corporation, Sunnyvale, Calif.).

To Determine if the Antibodies Produced in Rabbits to the Peptide

Ac-CRKQVMKKYLQSIKNKRY-COOH in accordance with example 17 recognize thepeptide R3P66 (SEQ ID NO 72), the enzyme-linked immunoadsorbent assay(ELISA) was performed. When antibodies recognize a peptide, a signal atOD405 is detected. FIG. 10 shows that these antibodies recognize R3P66but do not interact with homologous peptides PACAP-27 or VIP up to 30 ugof peptide concentration.

EXAMPLE 18 Airway Hyperresponsiveness in the Primate Acute Asthma Model

Male cynomolgus monkeys (Macaca fascicularis) used in this study weremaintained at constant temperature and humidity, with a twelve hourlight cycle. They were fed twice daily, except on an experimental daywhen food was withheld the night before the procedure. Water wasavailable ad lib at all times.

Airway hyperresponsiveness (AHR)(baseline) was measured 1 week beforethe control (no treatment) antigen challenge, and again 24 hrs afterantigen challenge. Antigen-induced airway hyperresponsiveness wasmeasured by a fall in the PC₁₀₀ (the concentration of methacholinerequired to cause a 100% increase in lung resistance) at 24 hr comparedto baseline. After 2 weeks rest, another baseline measurement of AHR wasperformed. One week later, peptides of this invention were administeredas an aerosol, 10 minutes before antigen challenge. After 24 hrs, AHRwas again measured, and the fall in PC₁₀₀ with treatment was compared tothat without treatment.

Experimental Procedure. On each experimental day animals wereanaesthetized with a ketamine/xylazine mixture (70:12 mg kg⁻¹ @0.1 mlkg⁻¹) while still in their cage. When unconscious they were brought intothe primate laboratory where they were placed in a supine position on aheated water blanket on a trolley. Ophthalmic ointment was wiped ontoeach eye, and 0.2 ml lidocaine (2%,) sprayed onto the larynx and overthe back of the throat. The jaws were held apart by a jaw spreader and acuffed 5.0 gauge endotracheal tube (with the end liberally smeared withxylocaine gel , 2%) was inserted with the aid of laryngoscope. Theanimal was then placed into a specially designed restraint chair suchthat the animal was in a slightly reclined but upright sitting position,secured only by a collar at the neck. A water-heated blanket surroundedthe animal.

The endotracheal tube was connected to a Harvard Ventilator adjusted todeliver 30-35 breaths per minute. Airflow was measured by a Fleischpneumotachograph and thoracic pressure was measured by a validynepressure transducer (as the difference between the pressure at thedistal end of the et tube and room pressure).

The pneumotachograph and validyne were connected to a pre-amplifier andthen into an MI² respiratory analyser. Using the primary signals of flowand pressure the analyser computed airway resistance and compliance (aswell as a number of other respiratory parameters). An initialmeasurement of 5-6 minutes was carried out to ensure the signals weresteady and that the values for resistance and compliance were withinrecognized limits.

Antigen challenge: This was an inhalation challenge with Ascaris suum.The supplied Ascaris suum extract was diluted tenfold with PBS to give a1000 ug/ml solution. The aerosol was delivered with a pressure drivenRainbow drop nebuliser (Puritan-Bennett) connected to a Bird mark 7Arespirator, set to deliver 15 breaths per minute. 30 breaths of antigenwere administered after which the acute bronchoconstriction wasmonitored for 15 min.

After the challenge had been finished the animal was weaned off theventilator, and when he could breath for himself was released from therestraint chair and laid supine on the trolley. When the normal reflexes(eye blink, swallow) had returned, along with muscle tone in the limbsthe animal was returned to its cage.

Peptide Administration: Peptides under evaluation were delivered byinhalation as above. Stock solutions of the peptides were diluted withsterile water to achieve a concentration of 0.5 ug/4 ul. From previousmeasurements the nebuliser had been demonstrated to deliver 4 ul/breath,and the number of breaths administered to each animal was adjusted todeliver the correct final concentration from the nebuliser. For eachpeptide the final concentrations delivered were as follows:

-   -   R3P0 (SEQ ID NO:5) −0.6 ug/kg    -   R3P76 (SEQ ID NO:82) −3 ug/kg    -   R3P82 (SEQ ID NO:88) −1.8 ug/kg

Methacholine challenge: Methacholine dose response curves were carriedout to assess the airway hyperresponsiveness. In the acute model, thiswas measured at +24 hour and compared to the responsiveness 7 daysbefore treatment. An aerosol of phosphate buffered saline (PBS) wasdelivered using a nebuliser as above. The aerosol was administered for15 breaths and then lung resistance was monitored for ten minutes.

Methacholine (Sigma) was made up at a concentration of 100 mg/ml in PBSand this stock solution was diluted with PBS to a final range ofconcentrations from 0.1 mg/ml through to 100 mg/ml. Methacholine (0.1mg/ml, 15 breaths) was administered followed by another ten minutesmonitoring. Successive doses of methacholine were administered with thedose increasing by a half-log at each step until either the lungresistance had doubled or the maximum dose of methacholine (100mg/ml)had been administered. The baseline (zero %) resistance was takenas the resistance achieved following the PBS administration. Theincrease in lung resistance (%) and the methacholine doses were enteredinto a spreadsheet and the PC₁₀₀ (the dose of methacholine to cause a100% increase in resistance) was calculated from a graph of dose againstresistance. These values were converted to log₁₀ values. The delta PC₁₀₀(+24 hr value−baseline value) for the treated study was compared to thatfor the control study.

Table 4 shows the PC₁₀₀ data for the three peptides. As shown by thedata, the peptides are effective against antigen-induced airwayhyperresponsiveness, and are thus likely to be a potential asthmatherapy.

TABLE 4 PC₁₀₀ data for all three peptide studies. Peptide (dose) R3P0(0.6 ug/mg) R3P76 (3.0 ug/kg) R3P82 (1.8 ug/kg) Delta log₁₀ PC₁₀₀Control Treated Control Treated Control Treated N 4 4 5 5 4 4 Mean*−0.325 −0.150 −0.468 +0.047 −0.567 −0.067 SD 0.177 0.152 0.128 0.2530.361 0.329 P(Treated vs Control) 0.240 0.031 0.087 % Inhibition of 54100 88 induced AHR *The larger the negative value, the morehyperresponsive the animal becomes.

All publications and patents mentioned in the above specification areincorporated herein by reference. Various modifications and variationsof the described compositions and methods of the invention will beapparent to those skilled in the art without departing from the scopeand spirit of the invention. Although the invention has been describedin connection with specific preferred embodiments, it should beunderstood that the invention as claimed should not be unduly limited tosuch specific embodiments. Indeed, various modifications of theabove-described modes for carrying out the invention which are obviousto those skilled in the field of molecular biology or related fields areintended to be within the scope of the following claims. Those skilledin the art will recognize, or be able to ascertain using no more thanroutine experimentation, many equivalents to the specific embodiments ofthe invention described herein. Such equivalents are intended to beencompassed by the following claims.

1. A polypeptide selected from the group consisting of SEQ ID NO:83 anda PEGylated form of SEQ ID NO:83, thereof, having selective pituitaryadenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonistactivity.
 2. A composition comprising a polypeptide of claim 1 incombination with a pharmaceutically acceptable carrier.
 3. A polypeptideconsisting of the amino acid sequence of SEQ ID NO:83.
 4. A compositioncomprising the polypeptide of claim 3 in combination with apharmaceutically acceptable carrier.